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CHAPTER 1
LITERATURE REVIEW
I. Introduction to Immunological Tolerance
The concept of immunological tolerance is a complex one that has evolved for the
past almost seventy years. This phenomenon was introduced by R. D. Owen in 1945 after
his influential observation of cattle twins. Owen noted that dizygotic cattle twins can
share a placenta, and the consequent anastamoses result in chimeras in which each twin
maintains blood cells from its sibling into adult life. Each adult cow is therefore tolerant
of the other twin’s blood cells and sustains a “red cell mosaicism” whereby the immune
system of one adult cow does not mount a response to the technically foreign cells of its
twin (1). At the same time, another influential and historic immunologist, Medawar,
documented that “foreign skin” could not be successfully or permanently used for skin
graft in humans except in the case of monozygotic twins (2). These seminal observations
exposed investigators to the concept of immunological tolerance and many speculated
that one could develop tolerance towards antigens to which one is exposed prior to
acquiring a fully developed immune system.
The previously mentioned observations postulated about immunological
tolerance, but it was Medawar in 1953 who first reported actively acquired immune
tolerance in experiments using fetal mice and chicken embryos (3). In these experiments,
recipient mouse embryos were injected with a cell suspension from an adult mouse of a
different donor strain. Eight weeks after birth, these mice were challenged with a skin
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graft from the same donor strain of mouse. A similar experimental protocol was carried
out with chicken embryos. The authors demonstrated that mice and chickens are not only
tolerant to an original inoculum of foreign donor cells to which they are exposed in fetal
life, but maintain this tolerance in adult life as demonstrated by tolerance of a skin graft
of the same antigenic constitution. This actively acquired tolerance is notably antigen
specific because mice and chickens retain the ability to reject a skin graft to which they
have not been tolerized. These findings suggested that immune tolerance could be
actively induced in an antigen specific manner after fetal exposure to a particular antigen
and that this tolerance could be maintained in adult life. Medawar was awarded the Nobel
Prize in Medicine in 1960 as a result of these findings. Medawar and his colleagues
would go on to identify interleukin-2 (IL-2) and vitamin A acetate as critical to
immunological tolerance long before a mechanism was revealed (4, 5) and his work
would contribute significantly to the concept of immunological tolerance. The role of IL2 and vitamin A in the immune system would be investigated in depth in years to come;
however, at the time, the mediators and mechanisms of tolerance and rejection remained
elusive.
The first observations of immune tolerance were not coincidentally made in the
context of maternal-fetal tolerance. Indeed, the fetal and placental tissue is partially
immunologically foreign to the mother, and therefore, the lack of an immune response
against such tissue is an interesting immunological phenomenon of tolerance and can be
considered a successful, though temporary, “transplant (6, 7).” There are numerous
immunological mechanisms in place to maintain maternal-fetal tolerance such as
expression of the non-classical HLA molecule HLA-G, and secretion of
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immunomodulatory human chorionic gonadotropin (hCG), as well as many other
mechanisms that directly promote a tolerogenic environment. For example, HLA-G
expressing cells have been shown to selectively promote tolerance inducing regulatory T
cell (Treg) differentiation (8-11) and hCG produced by placental tissue is chemoattractant
to Tregs (12). It follows that breakdown of the immunological phenomena contributing to
maternal-fetal tolerance have been shown to be responsible for conditions such as
immune hemolytic disease of the newborn, preeclampsia and spontaneous abortion (1316). Additionally, many mechanisms that promote maternal-fetal tolerance have also
been shown to be beneficial in inducing tolerance in a transplant setting (6, 8, 11, 17).
These critical clinical correlations highlight the importance of understanding the
principles of immunological tolerance through research. Maternal-fetal tolerance is a
fascinating phenomena and the tolerogenic nature of the placenta and umbilical cord
blood provides the foundation out of which our research model developed.
II. The Adaptive Immune System: Focus on Thymocytes
The human immune system consists of two distinct branches: innate and adaptive.
The innate immune system provides a first line of defense against an antigen responding
very quickly and in a non-specific manner. Activation of the adaptive immune system
occurs as a consequence of innate immune system mediators such as antigen presentation
and cytokine production and release. The adaptive immune system, composed of highly
specialized cells, then mounts a specific response against an antigen. An adaptive
response takes longer to generate, but results in long lasting, specific and important
memory against a particular immune stimulus. The main constituents of the adaptive
immune system are T and B cells. B cells are critical in the immune system, functioning
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as antigen presenting cells and producing antibody to facilitate the humoral immune
response. Thymocytes, or T cells, mature in the thymus from bone marrow
haematopoietic progenitors and undergo a complex process of positive and negative
selection before emigrating from the thymus. Upon maturation, naïve T cells leave the
thymus and home to secondary lymphoid organs, including the spleen, lymph nodes and
mucosal associated lymphoid tissue. In the periphery, T cells constantly survey for
foreign antigen and upon antigen recognition, function as critical mediators of cell
mediated immunity. T cells can be further divided into two primary subsets: CD8+
cytotoxic T cells, responsible for the specific killing of damaged or infected cells, and
helper CD4+ T cells, which will be the focus of this document.
Helper CD4+ T cells are essential players in orchestrating the adaptive immune
response by directing other immune cells to execute their function and coordinating a
complex and specific response to a pathogen. Activation of a CD4+ T cell occurs through
engagement of the T cell receptor (TCR) and antigen presented in the context of an MHC
class II molecule by an antigen presenting cell (APC). When a T cell encounters an APC
and recognizes the antigen which it expresses, the TCR complex binds to the
antigen/MHC complex. The CD4 molecule also participates in this interaction by binding
a different portion of the MHC molecule. This interaction initiates T cell activation and is
known as Signal 1. Signal 2 occurs via engagement on co-stimulatory molecule CD28 on
the T cell surface and CD80 or CD86 on the APC cell surface. The nature of these
interactions, including the type of APC, engagement of co-stimulatory molecules, and the
cytokine milieu in which the cellular interaction occurs direct a naïve CD4+ T cell to
differentiate into a specific CD4+ subset, each with distinct phenotypic markers and
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effector function (18). The cytokine milieu is primarily determined by the APC, which is
stimulated to secrete a variety of cytokines according to the antigen which it has
encountered and against which it has mounted a response. The coordination of T cell
activation is complex and results in mature T cells subsets functionally specialized to
react to the original antigen.
Today, four primary CD4+ T cell populations are recognized. The first CD4+ T
cell subset is Th1, which are functionally specialized to eliminate intracellular pathogens,
and primarily secrete effector cytokines interferon-γ (IFN-γ) and interleukin-2 (IL-2)
(18). One function of IFN-γ is to activate APCs such as macrophages, enhancing
phagocytosis and antigen presentation and resulting in a positive feedback loop of APC
activation and T cell stimulation (19). From a naïve CD4+ T cell, TCR stimulation and
activation in the presence of IL-12 and IFN-γ promote differentiation to the Th1 subset.
Transcription factors are also critical for T cell programming, and one principal
transcription factor expressed by Th1 cells is T-bet (18, 20). Transcription factors such as
T-bet are important in controlling the up- and down-regulation of subset specific gene
expression.
Naïve CD4+ T cells are directed to differentiate into Th2 cells after TCR
stimulation in the presence of IL-4 and IL-2 (18). Th2 cells respond to extracellular
pathogens and play a critical role in the activation of B cells, production of antibody and
promotion of humoral immunity. The Th2 subset also contributes to the pathogenesis of
asthma through secretion of cytokines including, but not limited to, IL-4 and IL-5 (18,
19). The principal Th2 cell specific transcription factor is GATA-3 (18, 20).
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The Th17 subset is controlled by the transcription factor ROR-γt and primarily
secretes the effector cytokines IL-17A, IL-17F, IL-21 and IL-22 (18, 20) which promote
Th17 mediated clearance of extracellular bacteria and fungi, as well as contribute to the
development of autoimmune disease (18). IL-6, IL-21, IL-23 and transforming growth
factor-β (TGF-β), primarily secreted by the interacting APC, direct the differentiation of
Th17 CD4+ T cells.
Similar to Th17 differentiation, TGF-β also promotes the differentiation of the
last primary subset of CD4+ T cells, regulatory T cells (Tregs). While plasticity has been
reported between Th17 and inducible Treg subsets, their differentiation program and
effector functions are antagonistic and mutually exclusive, in part through reciprocal
negative regulation of the other subset by Th17 and Treg specific transcriptional
regulators: ROR-γt and Foxp3, respectively (20, 21). Tregs themselves are quite diverse
and are the focus of the work discussed herein. The differentiation and effector function
of Tregs will be addressed in greater detail in the subsequent section.
Undoubtedly, CD4+ T cells are a functionally diverse class of adaptive immune
mediators. Our knowledge of this class of cells is constantly evolving and the diversity
even within Th1, Th2, Th17 and Treg subsets is becoming more apparent. It is important
to note that the nature of the interaction between the APC and naïve CD4+ T cell, and the
cytokine microenvironment in which that interaction occurs is critical in directing CD4+
T cell differentiation to each functionally specific subset.
III.

The Last Subset: Suppressor to Regulator

The final subset of CD4+ T cells is known today as Tregs. As a cell population,
Tregs are critical in the human immune system in the maintenance of self-tolerance and
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immune homeostasis. This cell population is focus of this document and the research
contained within. Though more detailed knowledge of Treg differentiation and effector
function was forthcoming, their identification began with further examination of the
aforementioned concept of immunological tolerance.
In an effort to uncover the mediators of immunological tolerance, Gershon
executed an elegant experiment in mice consisting of thymectomy and lethal irradiation
followed by bone marrow reconstitution with or without the simultaneous reconstitution
of thymocytes. After evaluating response to antigenic challenge, the authors noted that a
population of thymus derived lymphocytes induced tolerance in both other thymus
derived lymphocytes as well as bone marrow derived lymphocytes (22). In future
publications, Gershon et al observed that the suppressive thymocyte population was
sufficient for suppression of the antigen response of other thymocytes (23), that the
suppressive activity of these cells depends on the cell population which they are
regulating (24) and that certain in vitro conditions favored the induction of suppressor T
cells (25). Other groups also noted that thymocytes are capable of exerting a suppressive
effect on immune responses, including Tada et al. who further promoted the field of
suppressor T cells by specifically evaluating their influence on suppression of the B cell
mediated antibody response, among other studies (26-31). Complicated experiments
were conducted in which different populations of T and B cells were mixed together and
the antibody response to a particular antigen measured, with a decrease in antibody
response as evidence of suppressive activity. Numerous groups would go on to identify
that depletion of a “suppressive” or autoimmune protective thymocyte subset promotes
the development of autoimmune disease (32, 33). Likewise, investigators demonstrated
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that adoptive transfer of a pathogenic CD4+ thymocyte subset induces autoimmune
disease such as “wasting disease (34).” These findings suggested, and it was later shown,
that not only does a pathogenic population of CD4+ T cells exist, but also that the
activation of such a pathogenic CD4+ subset could be controlled or “suppressed” by an
additional and distinct CD4+ T cell subset (35, 36). While the concept of suppressor T
cells was controversial and heavily disputed among immunologists, research continued
and identifying and differentiating these pathogenic and protective CD4+ T cell subsets
became the goal of many investigators.
Despite widespread controversy, suppressor T cell studies had catalyzed research
in immunological tolerance and the cell population responsible for maintenance of selftolerance and immune homeostasis. After the discovery of actively acquired immune
tolerance, investigators sought to distinguish between pathogenic and suppressive or
autoimmune-preventive CD4+ T cells subsets. As previously mentioned, investigators
had demonstrated a population of pathogenic CD4+ T cells, as well as the ability to
control or suppress the activation of such a pathogenic CD4+ subset by an additional and
distinct suppressive CD4+ T cell subset (35, 36). Additionally, depletion of suppressor T
cells was shown to promote the development of autoimmune disease and anti-tumor
immunity (37). The existence of a suppressive immune cell subset had been demonstrated
in innumerable healthy and disease states in both mice and human research. Investigators
unsuccessfully sought to understand the differentiation and function of such suppressor T
cells; however, distinguishing features or markers of the cell subset remained elusive and
the immunological field of suppressor T cells endured harsh criticism. “The concept of
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antigen-specific suppression and suppressor factors simply became too complicated and
was dismissed as artifact (38).”
It wasn’t until 1995 when Sakaguchi revisited this concept and introduced
regulatory T cells with the identification of CD25, the IL-2 receptor alpha chain, as a
marker of the suppressive T cell subset (39). Sakaguchi removed CD4+ CD25+ cells
from otherwise healthy mice and documented the development of extensive autoimmune
disease. In confirmation, adoptive transfer of murine T cell suspensions depleted of the
CD25+ suppressive T cells was sufficient to elicit autoimmune disease in athymic nude
mice, some progressing to severe graft-vs-host-like wasting disease. Co-transfer of CD4+
CD25+ T cells with their CD25- counterparts prevented the development of
autoimmunity in a dose dependent manner. These data suggested that CD4+ CD25+ T
cells are responsible for maintaining self-tolerance and preventing autoimmune disease
(39) and elegantly clarified previous research. Soon after Sakaguchi’s seminal
observations, investigators demonstrated that not only does depletion of Tregs (CD4+
CD25+) elicit autoimmunity, but also augments immune responses to non-self antigens
(40). In addition, removal or reduction of Tregs also provokes potent tumor immunity in
normal mice (37). It has also been shown that CD4+ CD25+ Tregs enriched from normal
mice suppress allergy, promote graft tolerance, prevent graft-vs-host disease and maintain
maternal-fetal tolerance (40-44). The dysregulation of Treg number and/or function is
now known to play a critical role in the pathogenesis of cancer, allergy and various
human autoimmune pathologies such as multiple sclerosis, psoriasis, rheumatoid arthritis
and diabetes (41). This research established the critical role of Tregs in immune
homeostasis and self-tolerance and additionally demonstrated their importance in
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immune response to non-self antigens, autoimmune disease, cancer, allergy and maternalfetal tolerance. These data superseded controversy surrounding suppressor T cells and
incited forward progress in research in immunological tolerance.
IV.

Differentiation and Effector Function of Regulatory T Cells

In addition to CD25, other markers have been suggested to distinguish Tregs from
their potentially pathogenic counterparts such as cytotoxic T lymphocyte-associated
antigen 4 (CTLA-4) (45), but the most consistent Treg marker is expression of the
transcription factor Foxp3 (20, 42, 46). Foxp3 is said to be the master regulator of Treg
development and function (47-49) and expression of Foxp3 is sufficient to confer
suppressive activity to non-Treg CD4+ T cells (47, 48, 50). In these experiments, Foxp3
expression was both knocked-out of CD4+CD25+Foxp3+ Tregs and knocked-in to
CD4+CD25-Foxp3- T cells, and subsequently, regulatory/suppressive function was lost
or acquired in correlation with the loss or gain of Foxp3 expression. The importance of
Tregs and Foxp3 in the human immune system was further illustrated by investigation of
the severe autoimmune pathology of IPEX (immune dysregulation, polyendocrinopathy,
enteropathy, X-linked syndrome), which develops as a direct result of mutation in the
Treg specific transcription factor: Foxp3 (40, 42, 43, 51). This rare but devastating
disease characterized by the dysfunction of Tregs is evident as autoimmune
endocrinopathies such as diabetes, nail dystrophy, and skin pathology including alopecia,
dermatitis and bullous pemphigoid. IPEX illustrates the role of Tregs in the human
immune system in maintaining the normal homeostasis of diverse body systems and
preventing the development of autoimmune disease.
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It is important to note that human T cells transiently upregulate Foxp3 after T cell
receptor (TCR) stimulation and only genuine Tregs maintain stable expression of the
transcription factor (52). Investigators have shown that the difference between transient
and stable Foxp3 expression may lie in the methylation status of the Foxp3 locus, where
stable Foxp3 expression is mediated by methylation of CpG-rich regions of the gene
locus (53). The Foxp3 regulatory network is complex and wide reaching, including
molecules such as transforming growth factor-β (TGF-β) and GARP (53), which will be
discussed in a subsequent section. The factors which regulate Foxp3 expression and the
transcriptional regulation which Foxp3 exerts itself remain to be elucidated and are the
subject of much research. The complex Foxp3 regulatory network suggests the intricate
regulation of Treg differentiation and effector function.
Since the identification of suppressor T cells, we have learned a lot about
distinguishing Treg markers and their significance in maintaining self-tolerance and
immune homeostasis, but there is still much to learn about Treg differentiation. Tregs can
be produced in the thymus as a functionally mature subpopulation of T cells and can also
be induced from naïve CD4+ T cells in the periphery (54, 55). Tregs that develop in the
thymus are termed naturally occurring Tregs (nTregs) and mature through engagement of
MHC/self-peptide ligands expressed by thymic medullary epithelial cells, as regulated by
autoimmune regulator (AIRE) (55, 56). AIRE is a transcription factor which intricately
regulates expression of self-antigens by thymic medullary epithelial cells. The affinity of
the self-peptide/MHC/TCR interaction contributes to directing the differentiation of
nTregs through positive selection. T cells which bind strongly to self-antigens and could
potentially be self-reactive in the periphery are eliminated by negative selection. Upon
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emigration from the thymus, like their naïve non-Treg CD4+ T cell counterparts, nTregs
home to secondary lymphoid organs. Once established in the periphery, nTregs maintain
immune homeostasis to self-antigens and are capable of suppressing self-reactive
immune responses (55, 56). As previously mentioned, Tregs can also be induced from
naïve CD4+ T cells in the periphery and are then called inducible Tregs or iTregs.
Though nTregs and iTregs exert similar tolerogenic function in the human immune
system, they are both essential cell subsets in maintaining immune homeostasis and selftolerance.
The IL-2 receptor alpha chain, CD25 is one marker of functional Tregs and it
follows that IL-2 is essential for iTreg differentiation and survival (18, 20, 55). TCR
stimulation is also required for iTreg activation and differentiation including engagement
of co-stimulatory molecule CD28 with the CD80 or CD86 molecule on an APC, similar
to the activation process for other helper T cell subsets. Beyond TCR stimulation and costimulatory molecule engagement, exposure to molecules such as retinoic acid and
cytokines such as TGF-β and IL-10 has been shown to promote iTreg differentiation in
different models (55, 57-59). Furthermore, different APC subsets such as tolerogenic
dendritic cells (DC) and myeloid derived suppressor cells (MDSC) have been shown to
promote iTreg differentiation in mouse and rhesus macaque models (57, 58, 60-73).
Literature about tolerogenic DCs and MDSCs cites the important role of IL-10 or TGF-β
in promoting Treg differentiation, while other groups document the importance of
expression of indoleamine 2,3-dioxygenase (IDO) (74) or thymic stromal lymphopoietin
(TSLP) (75, 76). Regardless of the type of APC; TCR stimulation, co-stimulatory
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molecule engagement and the cytokine milieu in which this interaction occurs are
essential principles of human iTreg differentiation which are still under investigation.
While some groups have demonstrated the generation of human Tregs by methods
such as stimulation with antibody coated plates (77), culture with a murine stromal cell
line (78) or generation of Treg cell lines (79), it is clear that human iTreg differentiation
is different from murine iTreg differentiation and that the principles learned in murine
models cannot all be directly applied to a human system. One important example of this
is that addition of soluble exogenous TGF-β to cultures of human naïve CD4+ T cells
does not generate functional iTregs, where it does in murine cultures (80). Therefore, it is
necessary to further examine human iTreg differentiation. Human umbilical cord blood
(UCB) has been shown to be a source of iTregs and fetal CD4+ T cells have a strong
tendency to differentiate into Tregs that actively promote self tolerance as well as
maintain maternal-fetal tolerance (81-83). While human UCB is an inherently tolerogenic
environment, the cellular interactions and molecular mechanisms of human Treg
differentiation from both human adult peripheral blood and UCB remain elusive. Human
UCB will be utilized in the work discussed herein and determining the differentiation
program of human iTregs is the focus of the work described in this document.
After differentiation, Tregs maintain self-tolerance and immune homeostasis by
exerting dominant suppression over self-reactive or hyper-proliferative immune
responses via suppressing the activation, proliferation and/or effector function of a
variety of immune system cells (42, 84). While the exact mechanisms of Treg mediated
suppression are as yet unknown, it has been shown that Tregs can suppress other immune
cells in an antigen-specific and/or –nonspecific manner. One suggested mechanism of
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Treg-mediated suppression is cell contact-dependent inhibition of effector CD4+ T cells
via direct engagement of cell surface molecules such as CTLA-4 or release of inhibitory
cytokines such as TGF-β (40, 42, 84). Tregs have also been shown to directly inactivate
APCs from further stimulating an immune response, and to kill effector T cells or APCs
through the release of cytotoxic substances such as perforin and granzyme A (40, 42, 84)
which results in termination of the self-reactive or hyper-proliferative immune response.
Indeed, Tregs are indispensible in the human immune system and there are many
Treg-directed therapies already under investigation. Some groups are attempting to
deplete or inhibit Tregs in an effort to enhance anti-tumor immunity via toxin conjugated
IL-2 or anti-Treg specific monoclonal antibodies (42). Conversely, to abrogate
autoimmune pathologies such as multiple sclerosis, psoriasis, inflammatory bowel
disease or diabetes, other investigators are seeking to promote Treg proliferation by Tregstimulating monoclonal antibodies (42). Additionally, scientists are striving to achieve ex
vivo expansion of Tregs for patient transfusion to treat graft-vs-host disease or promote
transplant tolerance (42). In mouse models, ex vivo expansion and re-infusion of Tregs
has been shown to treat diabetes (85) and similar protocols are beginning to be tested in
humans (86-88). While many avenues are being investigated to manipulate Tregs in the
treatment of human disease, to date, scientists have been challenged by developing
efficacious therapies. Increasing our knowledge of human Treg differentiation and
development will be important in advancing our ability to treat numerous debilitating and
sometimes fatal human diseases.
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V.

The Monocyte: A Specialized Antigen Presenting Cell

An antigen presenting cell (APC) is an immune cell that can process and present
antigen in the context of a major histocompatibility complex (MHC) molecule in order to
stimulate other cells of the immune system, typically T cells, to generate an adaptive
immune response. Professional APCs are one class of APCs which are functionally
specialized to take up, via phagocytosis or receptor mediated endocytosis, process and
present antigen in the context of MHC. Professional APCs constitutively express MHC
and co-stimulatory molecules and include cell subsets such as DCs, B cells and
macrophages. Recently, monocytes have also been recognized as professional APCs and
their role in human immunology has been further investigated.
Monocytes are circulating mononuclear cells, capable of phagocytosis and
differentiation to macrophage or DC lineages after stimulation. It is largely accepted that
after stimulation and extravasation from the bloodstream, a monocyte begins the
differentiation program into macrophage or DC lineages and is no longer a monocyte, but
a “monocyte-derived” cell (89, 90). Because monocytes are circulating cells, antigen
encountered by a monocyte prior to extravasation can be retained, transported and
presented in other organ systems (89, 91). Some groups have also suggested that
circulating monocytes may transport tissue-restricted antigens to the thymus for display
during T cell maturation (89, 92, 93). This tissue-restricted antigen expression in the
thymus may promote differentiation of Tregs tolerant to such self-antigens which would
not be expressed by traditional AIRE mediated thymic medullary epithelial cells.
While human monocytes are a heterogenous population of cells, the TLR-4
accessory molecule CD14 is expressed on most monocyte subsets. CD14 is a
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glycosylphosphatidylinositol (GPI)-anchored protein expressed on the cell surface of
monocytes and other APCs such as macrophages, DCs and neutrophils (94-96). CD14
enhances the responsiveness of APCs to lipopolysaccharide (LPS) by participating in
LPS binding to TLR-4 (94-97). Indeed, investigators have suggested that the level of
CD14 expression determines the ability of the cell to respond to LPS (98). Some reports
have additionally shown that CD14 can respond to LPS without engagement of TLR-4
(95). CD14 can also interact with TLR-2 and can be shed as a soluble form: sCD14 (94,
97).
CD36 is another cell surface molecule expressed by monocytes and other cell
subsets such as platelets, erythrocytes, adipocytes and some endothelial cells. CD36 is a
member of the class B scavenger receptor family and also a TLR accessory molecule
which can form oxidized lipid ligand induced heterodimers with TLR-2, TLR-4 and
TLR-6 and promote sterile inflammation (94, 96, 97, 99-101). Reports show that CD36 is
a signaling molecule itself (102) and has functions other than aiding in TLR recognition
of oxidized lipid ligands. CD36 expression is tightly regulated during monocyte to
macrophage differentiation and may play a role in further promoting foam cell formation
(103); however, the mechanism of regulation is not known. Because of its ability to bind
oxidized lipids, CD36 has a purported role in atherosclerosis and cardiovascular disease
(100). It has additionally been shown to mediate internalization of erythrocytes
parasitized by Plasmodium falciparum, the causative agent of malaria (104). The
functions of CD36 are diverse, and CD36 can bind additional ligands including
components of the extracellular matrix like collagen, and thrombospondin-1 (TSP-1)
(103, 105).
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As mentioned previously, human monocytes are a heterogenous population of
cells. They can be divided into three main subsets based on expression of cell surface
molecules CD14, CD16 (FcγRIII) and CD64 (FcγRI): classic, activated/mature and
immunomodulatory/intermediate (91, 106-109). CD14+ CD16- monocytes are termed
classic because they most closely resemble the phenotype of the originally described
monocytes. Activated/mature monocytes are CD14+ CD16+ and more closely resemble
tissue macrophages. Activated monocytes constitute a smaller percentage of total
monocytes and are called inflammatory monocytes because they secrete more proinflammatory cytokines such as TNF-α than their CD16- counterparts (106, 110). CD16+
monocytes also express higher levels of CD32 (FcγRII) and MHC class II molecules and
express a different chemokine-receptor profile as compared to CD16- monocytes (106).
Both classic and activated monocytes differentiate into DC subsets after stimulation and
similarly stimulate T cell activation and proliferation (106, 110). The third monocyte
subset, immunomodulatory/intermediate, is distinguished by expression of CD14, CD16
and CD64 and has potent T cell stimulatory capability as this class expresses the highest
levels of HLA-DR and co-stimulatory CD86 of any monocyte subset (111). CD14+
CD16+ CD64+ monocytes exhibit characteristics of both monocytes and DCs and have
been suggested to be an intermediate phenotype between the two cell populations (106).
While the in vivo significance of the different monocyte subsets is still under
investigation, it is clear that there are distinct subsets according to expression of cell
surface molecules and various functional parameters, which may influence their ability to
induce CD4+ T cell subset differentiation.
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Various groups have reported that the functional immaturity, or antigen naïve
status, of an APC contributes to its ability to promote Treg differentiation (112, 113).
Others have documented modest differences between umbilical cord blood or newborn
and adult monocyte populations which may contribute to Treg differentiation (98, 114).
And the ability of circulating monocytes to express tissue-restricted antigen in the thymus
may promote intra-thymic differentiation of nTregs (89, 92, 93). However, the role of
monocytes in induction of human Treg differentiation is unknown. Of note, one clinical
study reported an increased Treg frequency in patients with acute myelogenous leukemia
(AML) where there are also increased numbers of circulating immature monocytes:
monoblasts (115). The function of monocytes in human Treg differentiation warrants
further investigation.
VI.

Transforming Growth Factor β: An Immunomodulatory Cytokine

Cytokines are known to influence the differentiation of a naïve CD4+ cell to a
specific effector subset and transforming growth factor-β (TGF-β) is one cytokine shown
to preferentially promote Treg differentiation in murine and human models. The TGF-β
superfamily consists of TGF-β1-3, bone morphogenetic proteins (BMPs), activins and
other related proteins, all of which play a role in cell development. TGF-β itself is a
pleiotropic cytokine with numerous roles in both modulating the immune response and
physiologic processes such as angiogenesis.
TGF-β superfamily ligands signal through a family of transmembrane
serine/threonine kinases divided into two subfamilies: type I and type II TGF-β receptors
(116). Upon binding to its receptor, TGF-β signals through Smad-dependent and Smadindependent pathways including Rho-like GTPase and MAP kinase pathways (116-118).
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Prior to binding receptor and initiating downstream signaling, TGF-β must be activated
from its latent form. TGF-β is secreted and exists in the extracellular milieu bound to a
propeptide, latency associated peptide (LAP) (116, 119). The TGF-β/LAP complex may
be further bound by latent TGF-β binding proteins (LTBPs) and anchored in the
extracellular matrix (119). Latent TGF-β has been shown, in some circumstances, to be
present on the cell surface and mediate cell function (120, 121), but neither LAP nor
TGF-β are transmembrane molecules.
Human GARP (LRRC32) is a transmembrane protein composed almost entirely
of leucine rich repeat (LRR) domains (122). LRR proteins are a large family of molecules
known to participate in protein-protein interactions and signal transduction (123). GARP
has been shown to be essential for LAP/TGF-β cell surface expression, and to be
expressed in humans only on activated Tregs (124-129). GARP undergoes signal peptide
cleavage prior to cell surface localization, and upon surface expression, is capable of
altering expression of other T cell activation markers (130). Furthermore, GARP has been
shown to mediate some of the suppressive function of Tregs and ectopic expression of
GARP induces expression of the Treg specific transcription factor: Foxp3 (121, 124129). Therefore, GARP is an activated Treg marker that is important in mediating Treg
specific cell surface expression of LAP/TGF-β and suppressive function.
As mentioned previously, the dissociation of LAP from latent TGF-β is a critical
regulatory step required for downstream TGF-β signaling. Thrombospondin-1 (TSP-1) is
a glycoprotein with a known role in angiogenesis (131, 132), that is also capable of
activating latent TGF-β via inducing a conformational rearrangement which results in the
release of LAP and biologically active TGF-β (131-135). CD36 serves as a cell surface
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receptor for TSP-1 and “expresses” the enzyme on CD36+ cells (131, 134, 135). Indeed,
CD36 has been shown to be required for TGF-β activation in a model utilizing rat
alveolar macrophages (135, 136). Additionally, among human monocytes, TSP-1 is
expressed highest in those that concomitantly express the highest levels of CD36 (109).
While TSP-1 and CD36 are important in TGF-β activation, TGF-β is likewise
important in promoting human Treg induction (133, 137-140). With the understanding
that dysregulation of Tregs is critical in autoimmune, and other, disease pathogenesis,
TGF-β is already under investigation in the treatment of various human diseases
including diverse autoimmune pathology (141-143) and fibrotic conditions like sclerosis
(144). Moreover, GARP was found to be expressed in the mouse placenta, a known
immunotolerant and Treg inundated environment (122), which relates this potential
contributor of Treg biology back to the concept of maternal-fetal tolerance and the
tolerogenic nature of the placenta and UCB. These findings all point to the significance
of the TGF-β/GARP and TSP-1/CD36 axis in Treg biology and immune tolerance and
homeostasis.
VII. The Role of Vitamin D in Human Regulatory T Cell Biology
The immune system is subject to influence by circulating endogenous factors as
well as exogenous factors, such as environmental exposure to aryl hydrocarbons in
cigarette smoke. One example of an endogenous factor that is shown to influence the
cells of the immune system including Tregs is Vitamin D, which can be consumed in
food products or synthesized upon exposure to sunlight.
Vitamin D deficiency is a highly prevalent, but relatively easily diagnosed and
treatable condition. Reports have documented a rise in vitamin D deficiency recently to
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as high as 50% of the white and up to 90% of the dark-skinned population in the United
States being vitamin D insufficient or deficient, defined by a serum vitamin D level less
than 30ng/mL (145). While vitamin D insufficiency is easily diagnosed and treated with
simple oral supplementation, most patients remain both undiagnosed and untreated (145149).
Nonambulatory, elderly, dark-skinned, institutionalized and chronically ill
individuals are among the most at risk for development of vitamin D insufficiency, and
would benefit the most from oral supplementation. The beneficial effects of vitamin D
supplementation on bone homeostasis and skeletal health have long been known, but the
favorable influence of vitamin D on the immune system is just recently being
investigated. Vitamin D supplementation has been show to have broad anti-inflammatory
effects, enhance cancer treatments, attenuate autoimmune reactions such as systemic
lupus erythematosis, rheumatoid arthritis and multiple sclerosis, and even to decrease the
severity of graft-vs-host disease (GVHD) (150-152), but the mechanism of these
immunomodulatory effects is largely unknown. The immunomodulatory influence of
vitamin D was also shown on peripheral blood human T cell constituents, where elevated
serum vitamin D was correlated with increased peripheral CD4+ and CD8+ T cells,
increased naïve T cells and increased levels of Foxp3 expression (153). It follows then,
that in another study, supplementation of vitamin D in otherwise healthy individuals was
associated with a significantly increased frequency of CD4+ Tregs (154) illuminating a
clinical correlation between exogenous vitamin D and immune-regulation.
Vitamin D receptors are widely expressed by immune cells and responsiveness to
vitamin D is cell type specific. The affect of vitamin D is mediated by binding and
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activation of the vitamin D receptor (VDR), which promotes heterodimerization with the
retinoid X receptor (RXR), nuclear translocation, binding of vitamin D response elements
(VDRE) in gene regulatory regions and modulation of transcription of target genes (155).
Vitamin D has been shown to promote monocyte differentiation into a macrophage
phenotype (156) and also to promote the development of tolerogenic, Treg inducing DCs
(146). Our focus will be on the influence of vitamin D on T cell differentiation,
particularly on promoting Treg induction.
Vitamin D plays a role in controlling the Th17/Treg differentiation axis, favoring
Treg induction as vitamin D directly inhibits transcription of IL-17A, a primary effector
cytokine of the Th17 subset, and directly induces expression of Foxp3 (157, 158). These
effects of vitamin D were found to ameliorate experimental autoimmune
encephalomyelitis (EAE), a mouse model of autoimmune multiple sclerosis (158, 159).
Vitamin D also stimulates expression of the Treg marker CTLA-4, directly promotes
Treg differentiation (160-162) and enhances Treg suppressive function (163).
The mechanism of action of vitamin D in immunomodulation is relatively
unknown, but Smad3, a downstream signaling molecule of TGF-β, is capable of
interacting with and serving as a co-activator of the VDR (164-166). TGF-β influences
CD4+ T cell differentiation and has a positive role in promoting Treg differentiation, so
the interaction of Smad3 and the VDR may potentially be a mechanism of vitamin D
mediated immunomodulation.
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VIII. The Influence of Alcohol on the Human Immune System: Focus on Regulatory T
Cells
Ethanol (EtOH) mediated impairments of immune competency have been
demonstrated in laboratory studies and clinical observations, specifically related to EtOH
exposure during fetal life. For example, animal models have shown dysregulated immune
responses as a result of EtOH exposure (167-171). The immunoteratogenic effects of
alcohol are apparent in that lymphocyte numbers and proliferative capacity in response to
stimulation are impaired in adult rats exposed to EtOH only in utero (172). Furthermore,
in utero EtOH exposure has long lasting effects, as adult mice exposed to alcohol only
during gestation have increased influenza-associated morbidity and mortality and
pulmonary viral titers, and decreased numbers of both B cells and influenza-specific CD8
T cells in the lungs following influenza infection (173). Secondary exposure to alcohol
further exacerbated these effects, which supports literature citing the general
immunosuppressive effects of alcohol exposure (173). Additionally, EtOH exposure has
been shown to interfere with the kinetics of Foxp3 , RORγt and T-bet gene expression,
the transcription factors required for human Treg and other CD4+ T helper subset
differentiation (174). Together, these data demonstrate that not only does EtOH have
significant immunosuppressive and immunoteratogenic effects, but also that alcohol
exposure restricted to gestation has immediate and long lasting immunosuppressive
effects through adult life in animal models.
Maternal alcohol consumption has been associated with a number of adverse
effects on the developing human fetus as well. These adverse effects include spontaneous
abortion, growth retardation, facial abnormalities, damage to the central nervous system,
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behavioral disorders, cognitive disabilities and increased susceptibility to bacterial and
viral infection (126, 175-179). Fetal alcohol syndrome (FAS) refers to the combination of
distinguishing facial features, reduced birth weight and behavioral and cognitive
impairment characteristic of children exposed to EtOH in utero (178). In addition to the
neuropsychological and behavioral disorders inherent in FAS, significant impairment of
immune function have been identified in these patients (168, 170, 171, 173, 175-177,
180). For these reasons, in 2005, the U.S. Surgeon General warned pregnant women and
women who may become pregnant to completely abstain from alcohol consumption
(178). Unfortunately, however, up to 30% of women report consuming alcohol at some
time during their pregnancy (175, 181, 182) and the prevalence of FAS in the United
States remains between 0.2-1.5 in every 1000 live births (126). Additionally, children
diagnosed with FAS incur annual mean medical expenditures nine times as high as those
of children without FAS (182).
Human FAS neonates have an increased incidence of bacterial infection,
including pneumonia, sepsis and meningitis, and viral infection caused by agents such as
influenza and cytomegalovirus (173, 175, 176). Increasing amounts of maternal alcohol
consumption during the three months prior, or at any time during pregnancy, significantly
increases the risk of neonatal infection by up to 6.83 fold (175). The increase in neonatal
infection observed after maternal alcohol consumption was higher than increases in
infection seen with mothers who smoke cigarettes or abuse cocaine or marijuana (175).
When adjusted for race and smoking, any drinking 3 months prior to conception or in the
first or second trimesters of pregnancy increased the risk of newborn infection by 2.5 fold
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(175). These data suggest a profound influence of isolated in utero exposure to alcohol on
the developing fetal/neonatal immune system.
While alcohol has been shown to influence the human immune system, very little
is known about the effect of alcohol, in utero or otherwise, on Treg biology or TGF-β.
Understanding these effects could be critical to comprehending certain human
pathologies including FAS and will potentially reveal novel treatment strategies for
addressing the increased risk of infection linked to FAS and the immunosuppression seen
in adult alcoholics.
IX.

The Placenta as a Source of Increasing Human UCB Cell Yields

The use of umbilical cord blood (UCB) as a source of hematopoietic stem cells is
increasing (183, 184) in the treatment of hematologic malignancies and non-malignant
disorders. UCB has presented a practical and beneficial alternative to bone marrow or
peripheral blood stem cell transplantation as the time to transplant and HLA matching
criteria for bone marrow and peripheral blood stem cell transplantation often present
challenges (183-186). Among the advantages of UCB transplantation are ease of
acquisition and availability of samples, leading to decreased time to transplant, less
stringent HLA matching requirements (187, 188) and decreased incidence of graftversus-host disease (GvHD) (185-187, 189, 190). The utility of UCB transplantation is
reinforced in studies that demonstrate UCB as a source of CD34+ hematopoietic
stem/progenitor cells (HSC) (190, 191); however, the limited HSC number obtained from
a single UCB sample presents challenges to widespread therapeutic application. While
UCB CD34+ HSC numbers are sufficient for transplantation of children, cell dose is a
critical determinant of successful transplantation and UCB is inadequate in this regard for

26

the treatment of most adults (190, 192, 193). Investigators have pursued three primary
avenues to combat this challenge: ex vivo expansion of UCB cell types (194), infusion of
more than one UCB unit per recipient (195-197), and increasing cell recovery from UCB
and placenta samples (198, 199). The importance of cell dose in successful transplant
highlights the need for optimization of these techniques to enhance the efficacy of UCB
transplantation.
In an effort to increase cell dose for UCB transplant, many groups have turned to
the human term placenta and found an additional source of HSC (198-203). The success
of UCB in clinical applications suggests that, if placenta derived cells are attainable and
exhibit comparable phenotypic and functional characteristics as UCB derived cells, then
placenta derived mononuclear cells would increase donor cell yield and further improve
transplant success.

CHAPTER 2
RESULTS
A fundamental component of the tolerogenic nature of the fetal/neonatal immune
system is the dominance of CD4+CD25+Foxp3+ regulatory T cells (Tregs); however, the
mechanism of induction and maintenance of such tolerance are largely undetermined. To
understand the induction of fetal/neonatal tolerance, we examined T cell biology in
human umbilical cord blood (UCB) samples. More specifically, I sought to determine the
cellular interactions and molecular mechanisms which promote the induction of
tolerogenic human Tregs.
I.

CD14+ CD36HI Monocytes Are Sufficient to Induce Treg Differentiation
from Human Naïve CD4+ T Cells

A. CD14+ cells promote human Treg induction from UCB mononuclear cells
To determine a mechanism by which the fetal immune system acquires tolerance,
we evaluated the T cell response in human umbilical cord blood (UCB) upon antigen
receptor stimulation. Freshly isolated UCB samples did not have a high starting
frequency of CD4+ Tregs. Indeed, only ~0.17% of CD4+ cells from freshly isolated UCB
were CD25+Foxp3+ Tregs (Figure 1). However, initial findings demonstrated that
mononuclear cells isolated from UCB exhibited increased Treg differentiation as
compared to mononuclear cells isolated from adult peripheral blood. Induced Tregs from
UCB retained their Foxp3 expression and Treg phenotype for up to 62 days in culture,
27
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demonstrating that these cells are stably induced Tregs.

Previous studies in the laboratory demonstrated both an increased frequency of
Treg differentiation from UCB mononuclear cells as compared to adult peripheral blood
mononuclear cells, and that such Treg induction required a non-T cell population.
Therefore, we sought to determine which non-T cell populations promote human Treg
differentiation. After systematic depletion of various cell subsets, we found that only
depletion of the CD14+ cell subset significantly reduced Treg induction from UCB
mononuclear cells. In these experiments, whole UCB exhibited ~85% of CD4+ T cells
differentiating to CD25+Foxp3+ Tregs, where the same frequency decreased to ~27% in
the absence of CD14+ cells (Figure 2). Moreover, culture of enriched CD14+ cells and
naïve CD4+ T cells resulted in a high frequency of CD4+ Treg differentiation (Figure 2).
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We therefore concluded that the CD14+ cell subset is critical for promoting Treg
differentiation from UCB mononuclear cells.

The increased frequency of Treg differentiation from UCB mononuclear cells
could have also been a result of UCB CD4+ T cells being intrinsically programmed to
become Foxp3+ Tregs after T cell receptor (TCR) stimulation. To test this hypothesis, we
cultured UCB naïve CD4+ T cells with TCR stimulating beads. Human CD4+ non-Tregs
(CD4+CD25-) failed to differentiate into Foxp3+ Tregs when cultured with TCR
stimulating anti-CD3 and anti-CD28 coated polystyrene beads (Figure 3). These data
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demonstrated that UCB CD4+ T cells are not intrinsically programmed to become
Foxp3+ Tregs upon TCR stimulation, but require interaction with the CD14+ cell subset
to induce such differentiation.
B. CD14+ CD36HI monocytes are sufficient to promote human Treg induction from
naïve CD4+ T cells
CD14+ cells are critical for induction of Foxp3+ Tregs from UCB naïve CD4+ T
cells; however, the CD14+ cell subset is a heterogenous population that includes many
different cell types including monocytes, dendritic cells and macrophages (94, 95). We
therefore sought to identify the specific subset of CD14+ cells sufficient to induce Treg
differentiation. To further distinguish CD14+ cell subsets, we evaluated the expression of
cell surface molecules, specifically CD36, on UCB CD14+ cells. CD36 is of interest
because it is capable of binding a TGF-β activating enzyme, thrombospondin-1 (TSP-1)
(131, 134, 135). Upon binding TSP-1, CD36 can subsequently tether this TGF-β
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activating enzyme to the cell surface of CD36+ cells. This is important because TGF-β is
produced in a latent form and requires proteolytic cleavage by enzymes such as TSP-1
to release biologically active TGF-β (119). Our group and others have demonstrated that
active TGF-β is critical in promoting human Treg differentiation. In our model, inhibition
of TGF-β signaling resulted in a significant and dose-dependent decrease in Treg
induction from whole UCB cultures (Figure 4). In fact, inhibition of other molecules
reported to promote Treg induction such as retinoic acid, aryl hydrocarbon receptor and
IL-10 resulted in no change in Treg induction in UCB culture (Figure 5). Inhibition of
TGF-β by an anti-TGF-β monoclonal inhibitory antibody resulted in similar abrogation of
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Treg differentiation (data not shown), further supporting the critical role of TGF-β in
human Treg induction.

As mentioned, TSP-1 activates latent TGF-β via proteolytic cleavage, resulting in
the release of LAP and biologically active TGF-β. CD36 serves as a cell surface receptor
for TSP-1 and “expresses” the enzyme on CD36+ cells. In fact, CD36 has been shown to
be required for TGF-β activation in a model utilizing rat alveolar macrophages (135,
136). To further investigate the role of TGF-β in our model of human UCB Treg
induction, we evaluated expression of CD36 on UCB CD14+ cells. Flow cytometry
showed that there were two distinct CD14+ cell subsets distinguished by their expression
of CD36: CD36HI and CD36LO (Figure 6). Therefore, we hypothesized that the CD14+
CD36HI population was the CD14+ cell subset sufficient to induce human Treg
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differentiation. To test the
hypothesis that CD14+ CD36HI
monocytes are sufficient to
promote human Treg
differentiation from naïve CD4+
T cells, cell subsets were sorted
from freshly isolated human UCB
based on expression of CD14 and
CD36 and cultured with enriched
human UCB naïve CD4+ T cells
at a ratio of 5:1. After 14 days,
cultures were evaluated by flow cytometry for Treg differentiation. CD14+ CD36HI cells
were found to induce significantly increased human Foxp3+ Treg differentiation as
compared to CD14+ CD36LO and CD14- populations. Flow cytometry of these cultures at
day 14 demonstrated that both whole UCB and culture with CD14+CD36HI monocytes
promotes a high frequency of Treg differentiation, 53 and 55.3% respectively, whereas
culture with other cell subsets induces less than 20% Treg differentiation among total
CD4+ T cells (Figure 7). When data from numerous cultures were compiled and
normalized to the Treg frequency of total CD4+ cells induced by whole UCB, it became
apparent that culture with CD14+CD36LO and CD14- cells induced significantly less
Treg differentiation than whole UCB or CD14+CD36HI co-culture (Figure 8). At day 14
of culture, CD14+ CD36HI monocytes also induced an increased absolute number of
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Tregs as compared to CD14+ CD36LO and CD14- subsets, correlating with the increased
population frequency seen by flow cytometry. Additionally, Tregs induced by the CD14+
CD36HI subset were functionally suppressive of syngenic responder CD4+ T cell
proliferation as demonstrated by an in vitro suppression assay. Naïve UCB T cells
proliferate in response to anti-CD3 antibody TCR stimulation; however, when either
whole UCB or CD36HI monocyte induced Tregs were added to culture, the proliferation
of syngenic naïve T cells was reduced significantly in a dose dependent manner (Figure
9). Of note, CD14+ CD36HI cells enriched from human adult peripheral blood were also
sufficient to induce Treg differentiation from adult naïve CD4+ T cells (Figure 10),
indicating that this phenomenon was not isolated to the human UCB environment.
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C. The role of TGF-β in CD14+ CD36HI monocyte mediated Treg induction
Inhibition of TGF-β signaling significantly decreased Treg induction from human
UCB mononuclear cells; therefore, we further pursued the potential role of TGF-β in
CD14+ CD36HI monocyte mediated Treg induction. Flow cytometry studies revealed an
increased level of LAP, the TGF-β binding pro-peptide, on the cell surface of CD14+
CD36HI monocytes as compared to their CD14+ CD36LO counterparts (Figure 11A).
Additionally, the majority (~57%) of LAP+ cells in freshly isolated human UCB were
among the CD14+ CD36HI subset (Figure 11B). Under physiological conditions, the
TGF-β/LAP complex may be bound by latent TGF-β binding proteins (LTBPs) and
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anchored in the extracellular matrix or, in some circumstances, be present on the cell
surface; however, neither LAP nor TGF-β are transmembrane molecules.
GARP, also known as LRRC32, is a transmembrane molecule required for cell
surface expression of LAP-TGF-β by activated Tregs and is also reported to mediate
some of the suppressive functions of human Tregs (124-129). Because of its ability to
bind the LAP-TGF-β complex, GARP is, therefore, a means by which LAP-TGF-β could
be tethered to the cell surface of CD14+ CD36HI monocytes. To date, GARP is only
known to be expressed in humans on the cell surface of activated Tregs (124-130). By
flow cytometric analysis, GARP expression was identified on CD14+ cells. More
specifically, studies revealed that CD14+ CD36HI monocytes expressed higher levels of
GARP than CD14+ CD36LO cells (Figure 12A). Additionally, in freshly isolated UCB,
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the majority (~71%) of GARP+ cells were CD14+ CD36HI (Figure 12B). GARP
expression by CD14+ cells was confirmed by both Western blot and immunofluorescence
(discussed in a later section). This is the first report of GARP expression on an immune
cell subset other than activated Tregs and provides a mechanism by which CD14+
CD36HI cells could tether LAP-TGF-β to their cell surface.
We also evaluated TGF-β production by CD14+ CD36HI, CD14+ CD36LO and
CD14- cell subsets. Cells were sorted based on expression of CD14 and CD36 as
previously described and cultured for 24 hours without stimulation. At 24 hours,
supernatants were subjected to TGF-β bioassay, which utilizes a secreated alkaline
phosphate (SEAP) TGF-β reporter cell line to detect TGF-β present in culture
supernatants. A TGF-β bioassay of supernatants from freshly isolated human UCB cell
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populations revealed that CD14+ CD36HI monocytes produced significantly higher levels
of TGF-β than either CD14+ CD36LO or CD14- populations (Figure 13). The average
TGF-β concentration in CD14+ CD36HI 24 hour supernatants was 6.43 +/- 0.35 pg/ml
(mean+/-SEM), while the average TGF-β concentrations in CD14+ CD36LO and CD1424 hour supernatants were 1.83+/-0.16 and 1.10+/-0.42 pg/ml (mean+/-SEM),
respectively (Figure 13). Of note, TGF-β was only detected by this bioassay after acid
treatment of supernatants, which activates latent TGF-β. The endogenously active form
of TGF-β was below the detection level of this assay (~1pg/ml) for all cell subsets tested.

Although we found that CD14+CD36HI monocytes produce significantly higher
levels of latent TGF-β than either CD14+CD36LO or CD14- populations, the level of latent
TGF-β production was not sufficient to explain the ability of CD14+ CD36HI cells to
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induce Foxp3+ Tregs. Addition of latent TGF-β to cultures of naïve CD4+ T cells and
CD14+ CD36LO cells did not restore Treg induction by this subset (Figure 14).

Supplementation of up to 5.0 ng/ml of active TGF-β to cultures of naïve CD4+ T cells
and CD14+ CD36LO cells partially restored Treg induction to the level of CD14+CD36HI
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monocytes (Figures 15 and 16). The lowest concentration of active TGF-β added in these
experiments (0.1ng/ml) was still approximately fifteen fold higher than that secreted by
CD14+ CD36HI monocytes as measured by TGF-β bioassay (Figure 16). Because
CD14+CD36HI monocytes produce high concentrations of latent TGF-β and
supplementation of soluble latent TGF-β to cultures of CD14+CD36LO cells does not
rescue Treg induction, we hypothesized that the cell surface bound latent form of TGF-β
is required for CD14+CD36HI monocyte mediated Treg induction.

D. The functional role of CD36 and GARP in human Treg induction
Data show that CD14+ CD36HI monocytes are sufficient to induce human Treg
differentiation from naïve CD4+ T cells and that this subset of monocytes expresses
higher levels of CD36, LAP and GARP and produces increased levels of latent TGF-β as
compared to their CD36LO and CD14- counterparts. However, the functional role of
CD36, GARP and cell surface bound TGF-β in Treg induction remained uncertain. To
evaluate the role of these molecules in human Treg induction, we established a genetic

42
system using THP.1 cells: a human acute monocytic leukemia cell line. A fraction of
THP.1 cells expressed CD36 and GARP (Figure 17A) and when cultured with UCB
naïve CD4+ T cells, irradiated THP.1 cells induced Treg differentiation (Figure 17B).

Additionally, THP.1 induced Tregs were functionally suppressive as demonstrated by in
vitro suppression assay (Figure 18).
To determine if CD36 and/or GARP play a functional role in human Treg
induction, GIPZ lentiviral shRNA vectors were purchased from Thermo Scientific Open
Biosystems targeting either CD36 or GARP, as well as a GFP expressing control vector.
After spinoculation, THP.1 cells were cultured and evaluated for expression of CD36 and
GARP at 72 hours post transduction. This transduction protocol was repeated 3-4 times
each with fresh THP.1 isolates. Transduction with an anti-CD36 shRNA vector resulted
in expression of GFP (Figure 19A) and a reduction in expression of CD36 as compared to
GFP vector control transduced THP.1 cells (Figure 19B). Both GFP expression (Figure
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20A) and a reduction in GARP expression as compared to GFP vector control transduced
THP.1 cells (Figure 20B) were demonstrated for anti-human GARP shRNA vectors as
well. GARP is rapidly recycled from the cell membrane, so cell surface and total GARP
were evaluated, and both forms were reduced upon transduction with anti-human GARP
shRNA vectors (Figure 20B). No vector achieved complete knock-down of either CD36
or GARP expression.

Transduced THP.1 cell populations were sorted based on GFP expression and
maintained in culture with puromycin, an antibiotic resistance marker included in the
GIPZ plasmid. If CD36 and/or GARP are required for human Treg induction from naïve
CD4+ T cells as we hypothesize, then knock-down of expression of either of these
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molecules will reduce Treg induction by that THP.1 population. Therefore, naïve CD4+
T cells were enriched from human UCB and cultured with untransduced THP.1 cells or
THP.1 cells transduced with the GFP control vector or shRNA vectors targeting CD36 or
GARP respectively. After 14 days of culture, untransduced and GFP vector control
THP.1 cells induced a similar frequency of CD4+ Treg differentiation, while knock-down
of CD36 or GARP expression resulted in a reduction of CD4+ Treg differentiation
(Figure 21A). This experiment was performed with 5-10 independent human UCB
samples and similar results were observed in all repetitions (Figure 21B). These data
support that expression of both CD36 and GARP are required for THP.1 mediated human
Treg induction.
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E. Confocal imaging studies of CD36 and GARP
Our data suggest that CD36 and GARP play critical roles in CD14+ CD36HI
monocyte mediated Treg induction. Potentially, co-localization of GARP and CD36
would place the inactive LAP-TGF-β complex bound to GARP in close proximity to the
TGF-β activating enzyme, TSP-1, bound to CD36. To address whether or not CD36 and
GARP are co-localized on the cell surface, we first enriched CD14+ cells from freshly
isolated human UCB by
magnetic bead isolation
(Figure 22) and subjected the
enriched
cells to immunofluorescent
labeling of CD36 and
GARP. Confocal imaging
studies and evaluation of the
appropriate controls (Figure
23) revealed that GARP is
expressed by CD14+ CD36+ cells as originally demonstrated by flow cytometry.
Additionally, imaging demonstrated that CD36 and GARP are not co-localized on the
cell surface of freshly isolated human CD14+ cells (Figure 24).
Also of note, by confocal microscopy, CD14+ CD36+ cells represented a
homogenous population demonstrating monocytic nuclear morphology of a “U-shaped”
or “horseshoe” nucleus (Figure 25). CD14+ CD36- cells did not stain positive for GARP
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expression, as expected based on flow cytometry data (Figure 26). This experiment has
been repeated with 5 independent human UCB samples.
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F. CD14+ CD36HI and CD36LO cells represent distinct monocyte subsets
Evaluation of select cell surface markers also revealed differences between
CD14+ CD36HI, CD14+ CD36LO and CD14- subsets. Human monocytes are a
heterogenous class of immune cells and recent studies have identified subsets within the
monocyte population based on expression of CD14, CD16 (FcγRIII), and CD64 (FcγRI).
The CD14+CD16- cells are termed “classical” monocytes (91, 106, 108). CD14+CD16+
cells more closely resemble mature tissue macrophages and are considered
“nonclassical.” An additional class of monocytes, CD14+CD16+CD64+, has been
identified more recently and is thought to be an intermediate phenotype between
monocytes and dendritic cells. While there is still controversy in the field over the
phenotypic characteristics and in vivo function of each monocyte subset, CD14+ CD36HI
and CD14+CD36LO cells exhibited differential expression of CD16 and CD64. CD14+
CD36HI monocytes were a relatively uniform population, exhibiting intermediate
expression of CD16 and high expression of CD64 (Figure 27A and C). Conversely, the
CD14+ CD36LO population demonstrated heterogeneity, but the majority were CD16CD64- (Figure 27B and C). While the in vivo significance of each monocyte subset is
unclear, CD14+ CD36HI and CD14+ CD36LO populations represent different classes of
monocytes based on expression of CD16 and CD64. Additionally, CD14+ CD36HI
monocytes express MHC class I and class II molecules. They do not express CD19, IgM
or CD8α, demonstrating that they are neither B cells nor tolerogenic dendritic cells,
respectively.
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G. The effect of LPS stimulation on CD14+ CD36HI monocyte mediated Treg
induction
Numerous groups have reported that the immature status of an antigen presenting
cell contributes to its ability to promote Treg differentiation. The general immunologic
immaturity of UCB suggests that the immaturity of antigen presenting cells isolated from
UCB could contribute to their Treg inducing ability. Therefore, we cultured naïve CD4+
T cells with either freshly isolated CD14+ CD36HI monocytes or after LPS mediated
activation of the same population with the hypothesis that LPS activation of this subset
would decrease their ability to induce Treg differentiation. CD14+ CD36HI cells express
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TLR4 and are therefore capable of responding
to LPS (Figure 28). We found that not only did
LPS treatment decrease the ability of CD14+
CD36HI cells to induce Treg differentiation as
hypothesized (Figure 29), but also decreased
CD36 and GARP expression by this subset
(Figure 30A). Data suggest that the LPS
mediated decrease in expression of CD36 and
GARP is specific, because expression of CD14
and CD47, another cell surface molecule capable of binding TSP-1, remained unchanged
after LPS stimulation. LPS treatment also moderately decreased TGF-β production by
CD14+ CD36HI monocytes (Figure 30B).
These data support that the
relative immaturity, or
antigenic naïvety, of
CD14+ CD36HI monocytes
contributes to their ability
to induce human Treg
differentiation. While LPS
activation may have
additional unintended
effects on CD14+ CD36HI
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monocytes, these data support previous studies demonstrating that expression of CD36
and GARP, as well as production of TGF-β, are important factors in CD14+ CD36HI
monocyte mediated Treg induction.

H. Summary
Overall, data demonstrate that CD14+ CD36HI monocytes are sufficient to induce
Foxp3+ Treg differentiation from naïve CD4+ T cells. Our studies also suggest that
CD14+ CD36HI monocyte mediated Treg induction is intimately dependent on the TGF-β
pathway. TGF-β is required for CD14+ CD36HI monocyte mediated Treg induction as
demonstrated by inhibition assays, and CD14+ CD36HI monocytes produce significantly
more latent TGF-β and express higher levels of CD36, LAP and GARP than CD14+
CD36LO and CD14- cells. TGF-β supplementation experiments demonstrate that active
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TGF-β supplementation partially increases UCB Treg induction by CD14+ CD36LO cells.
However, CD14+CD36HI monocytes produce high concentrations of latent TGF-β and
supplementation of soluble latent TGF-β to cultures of CD14+CD36LO cells does not
rescue Treg induction. Therefore, we hypothesized that the cell surface bound form of
latent TGF-β is required for CD14+CD36HI monocyte mediated Treg induction.
Through genetic manipulation of the THP.1 cell line, we have demonstrated that
knock-down of expression of CD36 or GARP significantly decreases THP.1 mediated
Treg induction. These studies suggest that CD36 and GARP expression are required for
THP.1 mediated Treg induction and point to the importance of the cell surface bound
latent form of TGF-β in CD14+ CD36HI monocyte mediated Treg induction.
Additionally, while CD36 and GARP are not co-localized on freshly isolated CD14+
cells as demonstrated by confocal imaging, these studies have not ruled out a physical
interaction between the two molecules.
In summary, we have shown that CD14+ CD36HI monocytes are sufficient to
induce Foxp3+ Treg differentiation from naïve CD4+ T cells. CD14+ CD36HI monocytes
produce significantly more latent TGF-β and express higher levels of CD36, LAP and
GARP than CD14+ CD36LO and CD14- cells. We have also demonstrated that CD36 and
GARP are required for THP.1 mediated Treg induction, illustrating the importance of cell
surface bound form of latent TGF-β is required for CD14+CD36HI monocyte mediated
Treg induction.
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II.

The Effect of Vitamin D on Human Treg Differentiation

Although vitamin D deficiency is a highly prevalent and easily diagnosed and
treated condition, most deficient patients remain both undiagnosed and untreated (145149). Treatment for vitamin D deficiency is oral supplementation of vitamin D and this
treatment benefits bone homeostasis and skeletal health, as well as certain features of the
immune system. The immune specific benefits of vitamin D supplementation, point to the
importance of advancing our understanding of how vitamin D influences the immune
response. Our focus is on the T cell constituents of the adaptive branch of the immune
system and we sought to understand how vitamin D influences the CD4+ T cell subset:
Tregs.
Previous studies demonstrated that human adult peripheral blood T cells are
affected by serum vitamin D concentration, because increased serum vitamin D was
correlated with increased peripheral CD4+ and CD8+ T cells, increased naïve T cells and
increased levels of Foxp3 expression (153). Another clinical study demonstrated that
supplementation of vitamin D in otherwise healthy adults was associated with a
significantly increased peripheral frequency of CD4+ Tregs (154). With the collaboration
of Pauline Camacho, MD and Barbara Sexton, RN, MS, at the Loyola University Medical
Center, and working with Stephanie Chapman, we obtained peripheral blood samples
from human volunteers between the ages of 18-80 years following specific inclusion and
exclusion criteria in order to evaluate the relationship between vitamin D and human
Treg biology. Exclusion criteria included, but were not limited to, presence of an active
malignancy in the past 5 years, use of immunomodulatory medications, autoimmune
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disease and pregnancy or lactation. Mononuclear cells were enriched from the peripheral
blood samples within 24 hours of collection and evaluated by flow cytometry for CD4+
Treg frequency. Vitamin D deficient patients were described as having a serum vitamin D
level of 0-30ng/mL and sufficient patients as having a serum vitamin D level of 31100ng/mL, in agreement with clinically accepted parameters (145, 147-149, 204). In this
pilot study, 5 vitamin D deficient patients and 5 age-matched vitamin D sufficient
patients were evaluated. We found that vitamin D deficient patients had a significantly
decreased CD4+ Treg frequency as compared to vitamin D sufficient controls (p<0.01)
(Figure 31). Specifically, we found the Treg (CD25+ Foxp3+) frequency of total CD4+
cells in freshly isolated peripheral blood from vitamin D sufficient patients to be 5.82%
+/- 0.76% and from vitamin D deficient patients to be 2.95% +/- 0.30% (mean +/- SEM)
(Figure 31). These data are in agreement with previously published studies demonstrating
a positive correlation between serum vitamin D concentration and Foxp3+ Treg
frequency in adult peripheral blood.
After confirming a correlation between serum vitamin D and Treg frequency in
adult peripheral blood, it was important to evaluate the influence of vitamin D in our
model of human Treg induction from UCB. Additionally, one study reported that vitamin
D levels do not correlate with Treg frequency in human UCB (205), which is in
opposition to data published from adult peripheral blood studies. Through the addition of
the biologically active form of vitamin D (1,25-dihydroxyvitamin D) to freshly isolated
UCB cultures, we have demonstrated that supplementation of vitamin D to whole UCB
cultures increases Treg frequency in a dose dependent manner as measured by flow
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cytometry at day 14 of culture (Figure 32A). The absolute number of CD4+ Tregs also
increased significantly with supplementation of 25nM vitamin D (Figure 32B).
The biological effect of vitamin D is cell type specific and mediated by binding
and activation of the vitamin D receptor (VDR) (155). In support of vitamin D
supplementation studies, VDR inhibition resulted in decreased Foxp3+ Treg
differentiation from whole human UCB cultures (Figure 33). Supplementation and
inhibition culture data are in agreement with previously published literature suggesting a
positive role for vitamin D in promoting human CD4+ Treg induction, and disagree with
the clinical study which reported no correlation between vitamin D levels and UCB Treg
frequency (205). These studies are a novel demonstration of the role of vitamin D in
promoting Treg induction in our model of human UCB culture.
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Our previous work has shown that CD14+ CD36HI monocytes are sufficient to
promote Treg induction from human naïve CD4+ T cells and recent data demonstrated
that vitamin D promotes Treg induction in whole human UCB cultures. Therefore, we
aimed to evaluate a possible relationship between vitamin D and CD14+ CD36HI
monocytes. We first evaluated expression of cell surface molecules CD36, GARP and
LAP on CD14+ CD36HI monocytes, and in data not shown, found no change in
expression of these molecules after treatment with vitamin D. We also observed no
difference in TGF-β production by whole UCB mononuclear cells with or without
vitamin D treatment (data not shown). We next sought to evaluate CYP.27B1 (1 alphahydroxylase) expression, the enzyme that activates vitamin D to its biologically active
form: 1,25-dihydroxyvitamin D3 or calcitriol (206). CYP.27B1 is known to be expressed
in the kidney, skin, bone and some immune cells (206, 207). Flow cytometric studies
demonstrated that CYP.27B1 was not only expressed by CD14+ cells from freshly
isolated human UCB, but that it was expressed at a higher level in CD14+ CD36HI
monocytes as compared to their CD14+ CD36LO and CD14- counterparts (Figure 34).
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The observation of increased CYP.27B1 expression in CD14+ CD36HI monocytes
suggested that vitamin D may play a role in CD14+ CD36HI monocyte mediated Treg
induction. To evaluate this hypothesis, CD14+ CD36HI, CD14+ CD36LO and CD14CD36- subsets were sorted from human UCB as previously described and cultured with
naïve CD4+ T cells enriched from freshly isolated human UCB. CD14+ CD36HI
monocytes and naïve CD4+ T cells were cultured with or without an inhibitor of TGF-β
signaling (SB431542) or a VDR inhibitor (ADMI3). SB431542 has been previously
shown to significantly abrogate human Treg induction from whole UCB cultures and we
have demonstrated that TGF-β plays a critical role in CD14+ CD36HI mediated Treg
induction. ADMI3 has been shown to decrease human Treg induction from whole UCB
cultures in our model (Figure 33). If vitamin D plays a role in CD14+ CD36HI monocyte
mediated Treg induction, then VDR inhibition would decrease Treg induction in this
culture similar to what is seen with TGF-β signaling inhibition. While VDR inhibition
resulted in a reduction in Treg frequency, the decrease was not as substantial as with
inhibition of TGF-β signaling (Figure 35A). Furthermore, TGF-β signaling inhibition
decreased the mean fluorescence intensity (MFI) of Foxp3 expression among total CD4+
T cells as compared to the Foxp3 MFI of naïve CD4+ T cells cultured with CD14+
CD36HI monocytes alone. VDR inhibiton did not result in as considerable of a decrease
in Foxp3 MFI among CD4+ T cells (Figure 35A). Additionally, supplementation of
active vitamin D to cultures of CD14+ CD36LO or CD14- CD36- cells and naïve CD4+ T
cells did not rescue Treg induction by these subsets (Figure 35B). These data suggest that
while vitamin D promotes human Treg induction in a whole UCB model, it may not be a
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critical component of CD14+ CD36HI mediated Treg induction. However, vitamin D may
play a role in maintaining the Treg inducing phenotype of the CD14+ CD36HI monocyte.
III.

The Influence of Ethanol Exposure on Human Treg Induction

FAS neonates have an increased incidence of bacterial and viral infection (126,
173, 175-177, 179, 182) and a potential explanation for these increased infection rates is
dysregulation of Tregs, which are capable of suppressing immune responses to invading
pathogens. To determine the effect of EtOH on human Treg biology, we utilized our
previously described model of ex vivo human Treg induction from whole UCB. While
this model does not exactly mimic the pathology of FAS, we believe this is a relevant
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model to study the neonatal immune system and potentially better understand the
increased risk of infection documented in association with FAS.
Increasing concentrations of EtOH were added to whole UCB culture wells from
25-50mM (167, 174, 180, 208-213). EtOH was added at the onset of culture only. At day
14 of culture, each treatment group was evaluated for Treg induction via flow cytometry.
We observed significantly decreased Treg induction with an EtOH treatment of 50mM,
measured as fold change from untreated whole human UCB control cultures (Figure 36).
These data suggest that EtOH can dysregulate human Treg induction.

Previous studies have demonstrated that TGF-β plays an essential role in human
Treg induction, so we were interested in whether or not EtOH could alter TGF-β
production by freshly isolated UCB mononuclear cells. To determine the influence of
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EtOH on TGF-β production, we cultured freshly isolated mononuclear cells from human
UCB in the presence or absence of EtOH and performed a TGF-β bioassay on the culture
supernatants after 24 hours. This TGF-β bioassay experiment revealed that at the same
EtOH concentration resulting in significantly decreased Treg induction, EtOH exposure
resulted in significantly decreased TGF-β production by UCB mononuclear cells (Figure
37). These data suggest that EtOH may exert its influence on human Tregs via
influencing the TGF-β pathway, which is known to play a critical role in human Treg
differentiation.
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IV.

A Method of Placental Perfusion to Increase Human UCB Donor Cell
Yields and Evaluation of the Resulting Cellular Constituents

UCB is an established source of HSC for transplantation in the treatment of both
hematologic malignancies and non-malignant disorders, and has many advantages in this
application including a low incidence of GvHD (185-190). Transplant success is
primarily dependent on HSC cell dose and the HSC yield derived from UCB is sufficient
in the treatment of children, but largely inadequate for the treatment of adults (190, 192,
193). Therefore, investigators are evaluating the human placenta as an additional source
of HSC (183, 188, 200, 202, 203) in an effort to increase total donor cell yields per
transplant unit. To establish a method of increasing donor HSC per transplant unit, we
evaluated whether a perfusion pump that mimics physiological blood flow would aid in
obtaining cells from the placenta while maintaining the integrity and viability of the
cellular constituents.
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Each placenta was first placed in a sterile tray and inspected for tissue integrity of
both the placenta and umbilical cord (Figure 38A). If the umbilical cord was not clamped
prior to collection, a clamp was placed at the end of the cord. A slipknot was also tied
with a silk suture around the umbilical cord close to its root from the placenta and
tightened gently to occlude both umbilical arteries and the umbilical vein. The cord was
cut proximal to the clamp and milked to remove all residual UCB into a sterile 50ml
conical tube. The excess umbilical cord was then cut to leave only 6-8 inches adjacent to
the slipknot. Sterile forceps, scissors, clamps and silk ties were used to make a two inch
incision in the cord and dissect out the umbilical vessels.
After priming the perfusion circuit (Medical Engineering Company, LLC, Bishop,
CA) with sterile saline, the single perfusion inflow tube was connected to the perfusate
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reservoir bag: one liter of Perfadex (addmedica) mixed with 500 mcg of Prostin VR
Pediatric at room temperature. Perfusate was pumped through the system and any air
bubbles were removed with a syringe through the stop cock.
The umbilical vein was then cannulated with a 10 French (Fr) catheter and the
arteries with 6 or 8 Fr catheters depending on the size of the vessels (Figure 38B). All
catheters were secured with silk sutures. The placenta was then sterilely attached to the
perfusion circuit by connecting the circuit outflow tubes to the umbilical arterial catheters
and the slipknot was released.
Initial pumping parameters were upstroke volume 200; stroke volume 0.5; pulse
rate 72. After initiating the perfusion pump, the perfusate flows through the arteries and
the effluent flows out of the umbilical vein. The pumping parameters can be adjusted to
achieve efficient perfusion. Samples were heparinized by the addition of 750 ul of 1,000
USP Units/ml heparin to each sterile 50 ml conical collection tube prior to collection.
Perfusate was sterilely collected from the venous catheter into heparinized 50ml conical
tubes (Figures 38C-D) until the effluent became clear. Samples were immediately placed
on ice and processed further.
After PAPFH perfusion of the placenta, samples were subjected to density
dependent centrifugation and isolation of mononuclear cells as described and further
analyzed for their HSC content. As mentioned previously, HSC cell dose is paramount in
successful UCB transplantation; therefore, determination of HSC frequency and absolute
cell number is critical in establishing the placenta as a potential HSC source. HSC are
self-renewing, multipotent cells that are additionally defined by their not having
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committed to a specific differentiation program or cell lineage and expressing the cell
surface marker CD34 (191, 194, 214). Therefore, each sample was stained with
antibodies against CD34 and lineage markers (Lin: CD3, CD14, CD16, CD19, CD20 and
CD56) and HSC were defined as being Lin- CD34+ (Figure 39A). The HSC frequency in
UCB and placental perfusate samples was comparable, ranging from 0.6 to 1.6% of total
live cells and averaging 1.1% and 0.9% in UCB and placenta samples respectively
(Figure 39B). The average total cell number recovered from UCB samples was 2.2 x 108
and average HSC number was 2.3 x 106. The average total cell number recovered by
placental perfusion was 3.0 x 107, a yield comparable to previously published methods
(198), and average HSC number was 2.3 x 105.
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One of the primary advantages of UCB transplantation, compared to bone marrow
or peripheral blood, is a decreased incidence of GvHD (185-190). This is thought to be
due, in part, to the immaturity of UCB derived lymphocytes. Therefore, we determined
the frequency of naïve T lymphocytes in both UCB and placenta samples, which we
defined as CD3+ CD45RA+. Similar to the HSC flow cytometry data, the frequency of
naïve T lymphocytes in human UCB and placental perfusate samples was comparable
(Figure 39C). Naïve T lymphocyte frequency ranged from 5.6 to 44% of total live cells in
UCB and placental perfusate samples. The average naïve T cell frequency was 28.7% and
17.4% of total live cells in UCB and placenta samples respectively (Figure 39D).
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T cell antigen reactivity could play a significant role in determining the level of
GvHD as instigated by donor T lymphocytes. To compare the antigen receptor reactivity
of T cells from both UCB and placental perfusate samples, mononuclear cells enriched
from either UCB or placental perfusion were stimulated by the addition of an anti-CD3
antibody. After 7 days of stimulation, cultures were evaluated for T cell differentiation
and proliferation. Expression of CD4 and CD8 was comparable between UCB and
placenta derived live cells (Figure 40A).

Expression of Foxp3 by activated T cells is required and sufficient for the
establishment of Tregs, which suppress hyperproliferative and autoreactive immune
responses (86, 215-217). Therefore, Foxp3 expression among both CD4+ and CD8+
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populations was evaluated at day 7 of cell culture. After a week of stimulation, similar
percentages of CD4+ and CD8+ T lymphocytes in both UCB and placental perfusate
samples expressed the transcription factor Foxp3 (Figure 40B). The absolute cell
numbers of each T lymphocyte population were calculated and found to be similar
between cultures of human UCB and placental perfusate mononuclear cells (Figure 40C).
Thus, T cell reactivity is similar in both human UCB and placental perfusate samples.
One challenge, as is found in all methods of UCB and placenta cell retrieval, is
the prospect of maternal cell contamination. This issue is being addressed and techniques
are being investigated to both detect and limit maternal cell contamination.

CHAPTER 3
DISCUSSION
I. CD14+ CD36HI Monocyte Mediated Induction of Human Treg Differentiation
from Naïve CD4+ T Cells
To date, the mechanism of induction and maintenance of human tolerogenic Tregs
has remained elusive. In my dissertation work, I sought to determine the cellular
interactions and molecular mechanisms which promote the induction of human Tregs,
specifically as it relates to the fetal/neonatal immune system.
The data presented in this manuscript have shown that UCB CD14+ CD36HI
monocytes are sufficient to induce human Treg differentiation from UCB naïve CD4+ T
cells, whereas CD14+ CD36LO and CD14- populations are not capable of promoting the
same induction. Through anti-TCR bead stimulation assays, we have additionally
demonstrated that Treg differentiation from UCB naïve CD4+ T cells is not a result of
intrinsic programming of UCB naïve CD4+ T cells, but that differentiation to Foxp3+
Tregs requires interaction with the CD14+CD36HI cellular subset. Additionally, CD14+
CD36HI monocytes enriched from adult peripheral blood are similarly capable of
inducing Treg differentiation from adult peripheral naïve CD4+ T cells. Therefore,
CD14+ CD36HI monocytes are uniquely sufficient to induce human Treg differentiation
from naïve CD4+ T cells: a phenomena which applies to both human UCB and adult
peripheral blood. Because monocytes are important circulating antigen presenting cells in
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the human immune system, capable of surveying the peripheral environment and
transporting antigen back to distant organ systems (89, 91, 106-108), I hypothesize that
CD14+ CD36HI monocyte mediated Treg induction is a critical mechanism by which the
human immune system promotes peripheral tolerance.
TGF-β has long been known to play a positive role in human Treg induction (57,
59, 120, 138, 142) and inhibition studies demonstrated that TGF-β; not IL-10, retinoic
acid, or AhR, is intimately involved in our model of human Treg induction as well. TGFβ is secreted and exists in the extracellular milieu in its latent form, bound by LAP (116,
119). The TGF-β/LAP complex may be further bound by latent TGF-β binding proteins
(LTBPs) and anchored in the extracellular matrix (119). Latent TGF-β has also been
shown, in some circumstances, to be present on the cell surface (120, 121). GARP is a
transmembrane molecule known to bind the latent TGF-β-LAP complex and tether it to
the cell surface of activated Tregs (124-130). Previously, GARP was only known to be
expressed in humans on activated Foxp3+ Tregs, and even shown to mediate some of
their suppressive function (126, 127, 129). Flow cytometric labeling of CD14+ CD36HI
monocytes revealed that they express increased levels of CD36, LAP and GARP as
compared to their CD14+ CD36LO and CD14- counterparts. Based on an exhaustive
PubMed search, this is the first demonstration of GARP expression on a human cellular
subset other than activated Tregs. Furthermore, GARP mediated cell surface expression
of LAP-TGF-β on activated Tregs plays a functional role in their suppressive function.
Therefore, so too could the cell surface “presentation” of LAP-TGF-β by GARP on
CD14+ CD36HI monocytes mediate their ability to induce Treg differentiation.
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In keeping with the importance of TGF-β in our model, CD14+ CD36HI
monocytes produce significantly increased levels of latent TGF-β as compared to CD14+
CD36LO and CD14- cellular subsets. TGF-β was only detected in this bioassay after acid
treatment of supernatants, which signifies that the TGF-β that was secreted was in its
latent form. The active form of TGF-β was below the detection level of this assay as
measured for all cellular subsets. Therefore, CD14+ CD36HI monocytes produce a
significant amount of latent TGF-β which could be secreted into the supernatant or
tethered to the cell surface by GARP. Taken together, these data indicate that latent TGFβ, potentially in its cell surface bound form, is critical in human Treg induction.
Through supplementation of active and latent TGF-β to cultures of CD14+
CD36LO cells, we have demonstrated that high concentrations of active TGF-β partially
restore Treg differentiation from cultures of CD14+ CD36LO cells and naïve CD4+ T
cells. Supplementation of soluble latent TGF-β did not increase Treg differentiation in the
same cultures. It is possible that CD14+ CD36LO cells cannot activate latent TGF-β to
promote Treg differentiation. The inability of CD14+ CD36LO cells to activate latent
TGF-β and promote Treg induction could potentially be explained by their decreased
ability to bind and present latent TGF-β by GARP, and their decreased expression of
CD36, which binds the TGF-β activating enzyme TSP-1. It is also possible that the cell
surface bound form of latent TGF-β is the form required for induction of Treg
differentiation. We hypothesize that while soluble TGF-β may contribute to human Treg
induction, cell surface-bound latent TGF-β, presumably tethered to the cell surface by
GARP, is required for CD14+ CD36HI monocyte mediated Treg induction from naïve
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CD4+ T cells. I hypothesize that the importance of cell surface bound TGF-β in our ex
vivo model of human Treg induction points to its potential significance under
physiological conditions as well. This is one possible avenue by which research and
clinical therapeutics directed at soluble TGF-β and human Treg induction could
potentially be improved. Perhaps instead of therapeutics which simply supplement
soluble TGF-β, delivery methods which provide TGF-β presented by GARP would be
more effective.
Further supporting the importance of cell surface bound TGF-β in human Treg
induction, genetic manipulation of CD36 and GARP expression in THP.1 cells has shown
that decreased expression of either molecule by THP.1 cells significantly decreases the
ability of that cell population to induce Treg differentiation. These data suggest that both
CD36 and GARP are required for THP.1 mediated human Treg induction from naïve
CD4+ T cells. These studies represent not only a novel demonstration of GARP
expression on a human cell subset other than activated Tregs, but also a novel functional
role of GARP expression in human Treg induction.
Confocal microscopy imaging studies demonstrated that CD14+ cells express
GARP and CD14- cells do not, as expected, but also that GARP and CD36 are not colocalized in freshly isolated CD14+ UCB cells. We have seen in other flow cytometry
experiments, that the majority of GARP exists intracellularly and that only a small
portion is expressed on the cell surface. These data suggest a tight regulation of GARP
localization in the cell and that, perhaps, very specific stimuli promote cell surface
expression of GARP. My hypothesis is that after interaction with a naïve CD4+ T cell,
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the CD14+ CD36HI monocyte receives a signal which promotes the cell surface colocalization of CD36 and GARP and subsequent activation of TGF-β, resulting in
induction of Treg differentiation. It is also possible that CD36 and GARP do not need to
physically interact to promote human Treg induction. Imaging studies of CD14+ CD36+
monocytes after 24 hours of culture with naïve CD4+ T cells are ongoing to determine
whether or not interaction with naïve CD4+ T cells promotes the co-localization of CD36
and GARP.
LPS treatment of CD14+ CD36HI monocytes decreases their ability to promote
Treg induction, their CD36 and GARP expression, and decreases their TGF-β production.
This LPS model represents a physiologic activation of CD14+ CD36HI monocytes by
antigenic stimulation and suggests that as this monocyte subset is naturally exposed to
antigen, it decreases Treg induction, potentially in favor of the desired effector CD4+ T
cell response, but this hypothesis has not been directly tested. While LPS activation may
have additional unknown effects on CD14+ CD36HI monocytes, these data support the
hypothesis that expression of CD36 and GARP, as well as production of TGF-β, are
critical factors in CD14+ CD36HI monocyte mediated Treg induction. These data also
suggest that the relative immaturity, or antigenic naïvety, of CD14+ CD36HI monocytes
contributes to their ability to induce human Treg differentiation.
Taken together, we have demonstrated that CD14+ CD36HI monocytes are
functionally specialized and sufficient to induce human Treg differentiation from naïve
CD4+ T cells, dependent on expression of CD36 and GARP. These findings suggest that
the cellular interaction between CD14+ CD36HI monocytes and naïve CD4+ T cells plays
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an important role in the generation of peripheral tolerance and perhaps plays a role in
establishment and/or maintenance of maternal-fetal tolerance as both CD36 and GARP
are expressed in the placenta (122, 218, 219). The ability to induce human Treg
differentiation makes CD14+ CD36HI monocytes and cell surface bound TGF-β unique
therapeutic targets for the treatment of autoimmune conditions, transplant rejection,
allergy and conditions of disrupted maternal-fetal tolerance. Additionally, inhibition of
this cell subset and/or the mechanisms involved in CD14+ CD36HI mediated Treg
induction could prove beneficial in impeding cancer pathogenesis.
II. The Role of Vitamin D in Human Treg Induction
Our data suggest that CD14+ CD36HI monocyte mediated Treg induction is an
important contributor to peripheral induced tolerance. This process, however, is certainly
not the only mechanism promoting peripheral tolerance and is also presumably subject to
influence by other immune cells and plasma factors.
Because supplementation of vitamin D increases, and VDR inhibition decreases
human Treg differentiation in whole UCB culture, vitamin D may be one such plasma
factor that promotes human Treg induction. Although CD14+ CD36HI monocytes express
high levels of the vitamin D activating enzyme, our data suggest that activation of
vitamin D is neither sufficient nor required for CD14+ CD36HI monocyte mediated Treg
induction. Inhibition of the VDR does not significantly abrogate Treg induction in this
model and supplementation of vitamin D to cultures of naïve CD4+ T cells and either
CD14+ CD36LO or CD14- APCs does not rescue Treg induction by these subsets.
Vitamin D treatment also does not alter TGF-β production by whole UCB mononuclear
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cells, another important aspect of CD14+ CD36HI monocyte biology and Treg induction.
While vitamin D may not directly mediate CD14+ CD36HI monocyte Treg induction, it
may play a role in maintaining the Treg inducing phenotype of the monocyte itself or
have an additional role in human Treg differentiation not yet identified.
Perhaps, CD14+ CD36HI monocytes express high levels of CYP27B1 and are
capable of activating vitamin D to its biologically active form, but this vitamin D acts via
other cell subsets and mechanisms to induce Treg differentiation. It is possible that
vitamin D produced by circulating CD14+ CD36HI monocytes acts on other APC subsets
or naïve CD4+ T cells directly, but that CD14+ CD36HI monocytes themselves are not
affected. It is also possible that CD14+ CD36HI monocytes are affected by vitamin D in a
manner that we have not yet tested. The TGF-β downstream signaling molecule, Smad3,
is capable of interacting with and serving as a co-activator of the VDR (164-166), which
provides a point of communication between vitamin D and TGF-β signaling. Our data
demonstrate that TGF-β is critical to the biology of CD14+ CD36HI monocytes, so the
interaction of Smad3 and the VDR could have unique consequences for this cellular
subset. The effect of vitamin D is very cell specific and it has already been shown to
promote monocyte differentiation (156) and the development of tolerogenic, Treg
inducing DCs (146). Therefore, vitamin D may uniquely maintain the Treg inducing
phenotype of CD14+ CD36HI monocyte by an as yet unknown mechanism. Future
directions of this research include determining the influence of vitamin D on CD14+
CD36HI monocytes and the mechanism by which vitamin D promotes human Treg
induction.
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Though many questions remain, we have demonstrated that vitamin D positively
regulates Treg differentiation in human whole UCB cultures. This is an important
concept to acknowledge because vitamin D deficiency is a highly prevalent condition,
most common in nonambulatory, elderly, dark-skinned, institutionalized and chronically
ill individuals. Additionally, vitamin D deficiency may have much further reaching
consequences beyond bone homeostasis and skeletal health. In fact, vitamin D is known
to be highly immunomodulatory. Vitamin D supplementation has been show to have
broad anti-inflammatory effects, enhance cancer treatments, attenuate autoimmune
reactions such as systemic lupus erythematosis, rheumatoid arthritis and multiple
sclerosis, and even to decrease the severity of graft-vs-host disease (GVHD) (150-152).
Therefore, our data suggest that management of vitamin D deficient patients and
monitoring of vitamin D oral supplementation should consider the patient’s immune
status and an effort should be made to evaluate and maintain immune homeostasis.
Further research could lead to the development of new or improvement of current
therapeutics with vitamin D for conditions such as autoimmune disease where the
increase of Treg populations is a desired clinical outcome.
III. The Effect of EtOH on Human Treg Induction
Vitamin D is an essential fat-soluble vitamin that can be ingested or synthesized
in our bodies after sun exposure, and therefore represents and endogenous means of
influence on human Treg induction. On the contrary, alcohol exogenously influences the
human immune system. Ethanol (EtOH) exposure dysregulates the immune response and
is immunosuppressive, moreover EtOH exposure only in utero significantly impairs
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immune competency and is immunoteratogenic (167-173). Human maternal alcohol
consumption is detrimental to the developing fetus, resulting in spontaneous abortion,
growth retardation, facial abnormalities, damage to the central nervous system,
behavioral disorders, cognitive disabilities, FAS and increased susceptibility to bacterial
and viral infection (126, 175-179). FAS refers to the combination of distinguishing facial
features, reduced birth weight and behavioral and cognitive impairment characteristic of a
child exposed to EtOH in utero (178).
FAS neonates have significant impairments in immune function (168, 170, 171,
173, 175-177, 180) and the risk of neonatal infection correlates with maternal alcohol
consumption; however, little is known about the direct influence of EtOH on the immune
system. Even less is known about the influence of EtOH exposure on human Treg
biology. While our model of ex vivo human Treg induction does not exactly mimic the
conditions of FAS, we believe that it provides a unique avenue to investigate this
question.
To that effect, we have demonstrated that at a concentration of 50mM, EtOH
exposure significantly decreases Treg induction from whole human UCB mononuclear
cell cultures. These data suggest that EtOH can significantly dysregulate the human
immune response by specifically blocking Treg differentiation. Human UCB is a close
physiological model to an in utero or neonatal environment and we believe that our data
supports that EtOH exposure via maternal consumption can have a significant effect on
the immune system of a developing fetus. Because the maternal fetal environment is
uniquely tolerogenic, dependent in part on Tregs, these data suggest that in utero EtOH
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exposure could potentially disrupt maternal fetal tolerance. Indeed, maternal alcohol
consumption has been associated with an increased rate of spontaneous abortion (178,
181).
TGF-β plays an essential role in human Treg induction and could be a means by
which EtOH alters human Treg differentiation. We cultured freshly isolated mononuclear
cells from human UCB in the presence or absence of EtOH and performed a TGF-β
bioassay on the culture supernatants after 24 hours. We found that at the same EtOH
concentration resulting in significantly decreased Treg induction, EtOH exposure results
in significantly decreased TGF-β production by UCB mononuclear cells. Therefore,
EtOH may act via the TGF-β pathway to decrease human Treg induction. TGF-β is not
only known to promote human Treg induction, but also to play a critical role in the
maintenance of maternal fetal tolerance. Therefore, these data further support the
detrimental influence that EtOH can exert on a developing fetus.
The significant decrease in both human Treg induction and TGF-β production
from human UCB mononuclear cells after EtOH exposure is thought-provoking and
incites a number of future directions. While we know that Treg frequency is decreased
after EtOH exposure, Treg function may be similarly impaired. It is also important to
determine the influence of EtOH on Treg function by exposing Tregs to EtOH and
directly evaluating suppressive activity. If EtOH exposure impairs Treg effector function
as we expect, then we will observe an increase in responder cell proliferation when
cultured with EtOH treated Tregs as compared to non-EtOH treated Tregs.
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We have demonstrated that CD14+ CD36HI monocytes are sufficient to induce
Foxp3+ Treg differentiation from naïve human CD4+ T cells. Therefore, I would like to
evaluate the effect of EtOH on CD14+ CD36HI monocyte expression of CD36, GARP
and LAP: molecules critical for human Treg induction. I would also like to directly
incubate either CD14+ CD36HI monocytes or naïve CD4+ T cells with EtOH and wash
prior to setting up a co-culture. EtOH treatment of only one cell subset prior to cell
culture would test whether EtOH acts on the CD14+ CD36HI monocyte and/or naïve
CD4+ T cell to decrease Treg induction. Additionally, CD14+ CD36HI monocyte
mediated Treg induction is abrogated by pretreatment of the CD36HI monocytes with
LPS, suggesting that exposure to immune activating signals alters the function of this
monocyte subset. It has been shown that EtOH blocks human monocyte activation in
response to LPS stimulation (168, 180, 208, 209, 211-213, 220). I hypothesize that EtOH
can similarly block the LPS mediated activation of the CD14+ CD36HI subset, which
could influence not only Treg induction, but also numerous other aspects of immune
activation.
While we have demonstrated that EtOH significantly reduces human Treg
induction and TGF-β production from human UCB mononuclear cells, many questions
remain. Understanding the effect of EtOH on the human immune system, particularly
Treg biology, is critical to comprehending the intricate maintenance of maternal fetal
tolerance and pathogenesis of FAS. It is necessary to continue this line of research
because, unfortunately, up to 30% of women report consuming alcohol at some time
during their pregnancy (175, 181, 182) and the prevalence of FAS in the United States
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remains between 0.2-1.5 in every 1000 live births (126). Advancing this research could
potentially reveal novel treatment strategies for preventing spontaneous abortion and
attenuating the increased risk of infection and immunopathology associated with FAS.
IV. Placental Perfusion as a Means to Increase Human UCB Donor Cell Yields
Vitamin D and EtOH may influence human Treg biology and have therapeutic
applications relevant to numerous human disease pathologies, but human UCB is itself a
therapeutic, providing a source of hematopoietic stem cells in the treatment of
hematologic malignancies and non-malignant disorders (183, 184). The advantages of
transplanting UCB compared to bone marrow or peripheral blood include ease and
availability of sample acquisition leading to decreased time to transplant, less stringent
HLA matching requirements (187, 188) and decreased incidence of graft-versus-host
disease (GvHD) (185-187, 189, 190).
As mentioned, UCB is a viable source of CD34+ hematopoietic stem/progenitor
cells (HSC) (190, 191); however, the limited cell number obtained from a single UCB
sample presents challenges to widespread therapeutic application. Investigators have
pursued three primary avenues to combat this challenge: ex vivo expansion of UCB cell
types (194), infusion of more than one UCB unit per recipient (195-197), and increasing
cell recovery from UCB and placenta samples (198, 199). The human term placenta has
been identified as an additional source of HSC (198-203) and we sought to evaluate
whether a perfusion pump that mimics physiological blood flow would aid in obtaining
cells from the placenta while maintaining the integrity and viability of the cellular
constituents.
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Since supplementing UCB transplantation with HSC obtained from placental
perfusion is the clinical goal, determining HSC frequency and absolute number is critical
in establishing the placenta as a potential cell source of HSC. Via PAPFH (Medical
Engineering Company, LLC, Bishop, CA), we determined that UCB and placental
perfusate contain a comparable HSC (Lin-CD34+) frequency averaging 1.1% and 0.9%
in UCB and placenta samples, respectively. The average HSC number recovered from
UCB samples was 2.3 x 106. The average total cell number recovered by placental
perfusion was 3.0 x 107, a yield comparable to previously published methods (198), and
average HSC number was 2.3 x 105. These data indicate that the placenta, as perfused by
PAPFH, represents a feasible source of HSC to increase total donor HSC number by 10%
per transplant unit. While we do not know the clinical significance of this increase, the
critical importance of cell dose in successful transplant points to the value of any increase
in HSC cell number.
After determining that placental perfusate is a viable and potentially important
source of HSC to increase total donor cell yields from UCB alone, we sought to evaluate
other parameters of successful transplantation as they applied to placental perfusate.
Decreased incidence of GvHD is one of the primary advantages of UCB as compared to
bone marrow or peripheral blood transplantation (185-190). This is thought to be due, in
part, to the immaturity of UCB derived lymphocytes. Therefore, we evaluated the
frequency of naïve T lymphocytes in both UCB and placenta samples and found that the
frequency of naïve T lymphocytes in human UCB and placental perfusate samples was
comparable. While naïve CD4+ T cell frequencies were similar in UCB and placental
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perfusate, these data did not necessarily imply similar reactivity among naïve CD4+ T
cell populations. In order to compare the antigen receptor reactivity of T cells from both
UCB and placental perfusate samples, mononuclear cells enriched from either UCB or
placental perfusion were stimulated by the addition of an anti-CD3 antibody. Cultures
were evaluated for T cell differentiation and proliferation and we found that CD4 and
CD8 expression was comparable between UCB and placenta derived cultures.
Additionally, similar percentages and absolute cell numbers of CD4+ and CD8+ T
lymphocytes in both UCB and placental perfusate samples expressed the transcription
factor Foxp3. Therefore, not only do UCB and placental perfusate have similar naïve T
cell composition, but also T cell reactivity is similar in both samples, including
differentiation of immunoregulatory Foxp3+ T cells. These data suggest that the risk of
GvHD as mediated by donor T lymphocytes would be comparable between UCB and
placental samples: an important advantage of UCB transplantation. The exact explanation
of why UCB has a decreased incidence of GvHD is unknown, but our data suggest that
UCB is a uniquely tolerogenic environment, dominated by CD14+ CD36HI monocyte
mediated TGF-β production and Treg induction. Therefore, in future studies, I would like
to evaluate CD14+ CD36HI monocyte composition and function in placental perfusate.
Interestingly, GARP, a molecule that we have demonstrated to be required for human
Treg induction by CD14+ CD36HI monocytes, is expressed in the endothelial cells of the
mouse placenta (122). This finding suggests to me that some of the same principles
observed in UCB could be applied to the tolerogenic, Treg rich environment of the
placenta and the maintenance of maternal fetal tolerance. I would be very curious to
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explore the role of GARP in the human placenta and determine if it functions in a similar
Treg inducing capacity as we have observed on CD14+ CD36HI monocytes.
Taken together, our data demonstrate that PAPFH is an efficient and feasible
method of placenta perfusion that increases HSC donor cell yields as compared to UCB
samples alone. The importance of cell number in successful UCB transplantation
highlights the need for optimization of these techniques to enhance HSC retrieval and the
efficacy UCB transplantation. Additionally, these data suggest that placenta derived
lymphocyte populations by this method are phenotypically and functionally comparable
to UCB cells. These findings propose that the therapeutic advantages of UCB, including
decreased incidence of GvHD, may also be applicable to placenta derived cells. PAPFH
is a practical method of obtaining additional HSC per transplant unit, and we believe this
study represents an important advancement in the field of UCB transplantation.
V.

Conclusion

While we believe that our research is a significant contribution to understanding
the human immune system and specifically, fetal tolerance, there are certainly many
questions remaining, some of which are already under investigation in our laboratory.
The importance of CD14+ CD36HI monocyte induced Treg differentiation and the
requirement of CD36 and GARP in this model have far reaching influence and potential
application in numerous clinical scenarios. For example, it is conceivable that treatment
of bone marrow or solid organ transplant tissue with a therapeutic to promote GARP
expression would, in turn, enhance transplant tolerance. Perhaps GARP and CD36
expression can be induced in the human placenta and prevent spontaneous abortion, not
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limited to that seen as a consequence of maternal alcohol exposure. What if tolerance to
an antigen could be induced by systematic exposure to said antigen in the context of a
CD36 and GARP expressing vector? And what if this became a customized means to
prevent or treat allergy? I would be thrilled and truly blessed to watch the evolution of
these concepts and hopefully be involved in some of the research and clinical application.

CHAPTER 4
MATERIALS & METHODS
UCB Collection
UCB samples were collected by nurses in the Birth Center at Gottlieb Memorial Hospital,
a Loyola University Health System affiliate. UCB was collected into sterile,
anticoagulant treated BLOOD-PACK™ units (Fenwal, Inc., IL) and processed as soon as
possible after collection.
Mononuclear Cell Isolation from UCB and Placental Perfusate
Heparinized UCB samples were diluted 1:1 with room temperature 1 x PBS.
Mononuclear cells were then enriched by density dependent centrifugation using
Lymphocyte Separation Medium (Cellgro). The buffy layer containing mononuclear cells
was then carefully extracted by pipetting. The centrifugation protocol was repeated 2-3
times until the buffy layer contained minimal red blood cell contamination. Mononuclear
cells were then collected, counted and further subjected to flow cytometry cell sorting or
cell culture protocol.
Flow Cytometry
Cells were washed in 1 x PBS with 1.0% FCS, 0.1% sodium azide, and stained with the
indicated mouse anti-human antibodies (all Biolegend) for 30 minutes. A Foxp3
Fix/Perm Buffer Set (Biolegend) was utilized for intracellular staining of the transcription
factor Foxp3. For anti-GARP staining, cells were washed as described, incubated with a
86

87

purified anti-human GARP antibody (Biolegend) for 30 minutes at 37˚C, washed and
subsequently incubated with a goat anti-mouse IgG antibody (Biolegend) for 30 minutes.
Data was collected using FACS Canto II (Becton Dickinson) and data analysis was
completed on FlowJo software (Tree Star, Inc.).
Cell Sorting and Enrichment
Freshly isolated mononuclear cells from blood samples were washed in 1 x PBS with
2.0% FCS and incubated with mouse anti-human CD14-FITC and CD36-PE antibodies
(Biolegend) for a minimum of 30 minutes in the dark at room temperature. Cells were
washed and resuspended in 1 x PBS with 2.0% FCS and sorted using FACS Aria (Becton
Dickinson).
Total CD4+ T cells, naïve CD4+ T cells and CD14+ monocytes were enriched from
whole UCB mononuclear cells via BD IMag Enrichment Sets according to BD protocol.
Cell Culture
Enriched cells were cultured in 48 well or 96 well U-bottom plates in RPMI-1640
Medium (Thermo Scientific) with 10% FCS (Atlanta Biologicals), β-mercaptoethanol (50
uM), sodium pyruvate (1 mM), L-glutamine (2 mM), penicillin (100 I.U./ml),
streptomycin (100 ug/ml), HEPES (10 mM), and MEM essential and non-essential amino
acids (Invitrogen). Cultures were supplemented with exogenous IL-2 (PeproTech) at 10
ng/ml and soluble α-CD3 (eBioscience) at 0.2 ug/ml. Cultures were continued for up to
21 days. Media was changed every 2-3 days and IL-2 concentrations were maintained
throughout.
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Polystyrene beads were incubated with 10ug anti-human CD3 and 10ug anti-human
CD28 per 100ul bead suspension overnight at room temperature, washed in 1 x PBS and
blocked in 1 x PBS with 10% BSA for 2 hours. After blocking, beads were washed again
and resuspended in cell culture medium to 2 x 106 beads per 50ul media. For stimulation,
1 x 106 cells were incubated with 50ul of prepared bead suspension for 1 hour at 37˚C
before transferring to cell culture plates. When polystyrene beads were used in culture, no
additional soluble anti-human CD3 was added.
Where indicated, an inhibitor of TGF-β signaling, SB431542 (Sigma-Aldrich) was added
to cell culture at 1-10µM concentrations. Latent or activated recombinant human TGF-β
(R&D Systems) was added to cell cultures at the indicated concentrations.
For LPS pretreatment, sorted CD14+ CD36HI cells were cultured overnight in cell culture
media with 100ng/ml LPS. After 24 hours, cells were washed in media three times and
used in cell culture or flow cytometric applications.
TGF-β Bioassay
Cells were cultured in bioassay medium, DMEM with penicillin (100 I.U./ml),
streptomycin (100 ug/ml) and 1 x Nutridoma (Roshe), and supernatants harvested for
analysis. MFB-F11 cells (TGFβ1 KO MEFs transfected with a SMAD-binding element
promoter fused to a secreted alkaline phosphatase (SEAP) TGFβ reporter gene) were
maintained in culture with MFB-F11 culture media, DMEM with penicillin (100 I.U./ml),
streptomycin (100 ug/ml) and 10% FCS. One day prior to harvesting supernatants for
analysis, MFB-F11 cells were counted and seeded at 4 x 104 cells per well of a 96 well
flat bottom tissue culture plate and incubated overnight at 37˚C. The next day, seeded
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wells were washed twice with 100ul room temperature 1 x PBS and 100ul bioassay
medium was added. MFB-F11 cells were allowed to rest for 2 hours in bioassay medium
before the addition of culture supernatants. TGF-β titration controls were established up
to 1000pg/ml using human recombinant activated TGF-β (R&D Systems). To prepare
culture supernatants, 5ul 1N HCl was added per 100ul supernatant and incubated at room
temperature for 15 minutes before neutralization with 5ul 1N NaOH per 100ul
supernatant. After acid treatment and neutralization, 100ul culture supernatant or TGFβ
control was added to each MFB-F11 seeded well and the plate was incubated at 37˚C
overnight.
Detection of SEAP was measured by a Chemiluminescent Reporter Gene Assay System
(Applied Biosystems) according to protocol. Luminescence data were converted to
corresponding supernatant TGF-β concentrations in pg/ml according to the TGF-β
titration curve for each individual experiment.
Proliferation Assay
To perform a proliferation assay, CD4+ CD25+ Tregs were enriched from indicated day
14 cultures via a Human Regulatory T Lymphocyte Separation Set – DM (BD IMag).
Additionally, total CD4+ T cells were enriched as previously described from syngenic
samples that had been frozen since the day of collection. Cells were cultured in 96 well
U-bottom plates at increasing Treg : Responder Tcell ratios in cell culture media with
soluble α-CD3 (eBioscience) at 0.2 ug/ml. The same number of responder CD4+ T cells
were cultured in each well with an increasing ratio of Tregs added to each subsequent
well. Wells of either responder CD4+ T cells or Tregs alone were cultured as controls for
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proliferation. Culture was maintained for 7-10 days at 37˚C until measure of cell
proliferation by Cell Titer Glo® Luminescent Cell Viability Assay (Promega) according
to protocol.
shRNA Based Knock Down of CD36 or GARP Expression
shRNA based knock-down of either CD36 or GARP in the human monocyte cell line,
THP.1, was carried out using GIPZ lentiviral shRNA vectors (Thermo Scientific Open
Biosystems) targeting either CD36 or GARP and an empty vector control. These vectors
arrived as individual bacterial clones. Each clone was cultured, plasmids were prepared
using a Midi Prep Kit (Qiagen), and restriction digests were performed to confirm
plasmid integrity. Using Lipofectamine 2000, 293T cells were transfected with each
shRNA plasmid and the resulting viral supernatants were used in spinoculation of THP.1
cells. After spinoculation, THP.1 cells were cultured and evaluated for expression of
CD36 and GARP by flow cytometry at 72 hours post transduction. Transduced THP.1
populations were sorted based on GFP expression and maintained in culture with
puromycin, an antibiotic resistance marker included in the GIPZ plasmid. Prior to culture
with naïve CD4+ T cells, THP.1 cells were irradiated at 3,000 rad.
Confocal Staining and Imaging
The desired cell population for imaging was washed in 1 x PBS and resuspended to
50,000 cells per 100ul sterile 1 x PBS. 100ul of the cell suspension was cytospun for 10
minutes onto Superfrosted PLUS Slides (VWR). Cell suspension was encircled with a
PAP pen and allowed to dry. Cells were fixed with 37˚C 4% PFA (filtered) for 15
minutes and washed 3 times with sterile 1 x PBS for 5 minutes each wash. To block, a
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solution of 10% BSA and 3% normal goat serum in sterile 1 x PBS was added to slides
and allowed to incubate at room temperature for a minimum of 30 minutes. Blocking
solution was gently poured off, and without washing, primary antibodies were diluted in
sterile 1 x PBS and added to slides: mouse anti-human GARP at 1:100 and rabbit antihuman CD36 at 1:800. Slides were incubated overnight in the dark at 4˚C.
After overnight incubation, slides were washed 3 times with sterile 1 x PBS for 5 minutes
each wash. Secondary antibodies (goat anti-mouse IgG and goat anti-rabbit IgG,
respectively) were diluted at 1:500 in sterile 1 x PBS, added to slides and incubated in the
dark at room temperature for 1 hour. Slides were washed 3 times with sterile 1 x PBS for
5 minutes. Hoescht nuclear stain was diluted at 1:20,000 and incubated on slides for 2
minutes before slides were washed again 3 times in sterile 1 x PBS. Slides were allowed
to dry for a few minutes before adding mounting media and carefully applying coverslips.
Slides were stored at 4˚C until imaging.
Placenta Collection and Perfusion
Full term placentas were collected in sterile containers in the Labor and Delivery
Department at Loyola University Medical Center and processed immediately. The
processing protocol is described in the main text.
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